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ABSTRACT
A-Kinase Anchoring Proteins (AKAPs) comprise a family of roughly 70 scaffolds
that anchor PKA and other enzymes to a variety of subcellular compartments. Although
characterized as “anchoring proteins”, some AKAPs are not spatially and temporally
static but can undergo dynamic subcellular trafficking, thus repositioning anchored
enzyme complexes within the cell. Gravin (also called SSeCKS or AKAP12) anchors
PKA and other enzymes to the plasma membrane but redistributes to the cytosol upon
intracellular calcium ([Ca2+]i) elevation. However, the impact of gravin redistribution on
PKA-dependent signaling pathways is poorly understood. We hypothesize that through
Ca2+-mediated redistribution, gravin facilitates cross-talk between Ca2+-dependent and
PKA-dependent pathways.
First, we tested this by characterizing the impact of [Ca2+]i elevation on the
distribution of gravin and PKA. In cells expressing gravin-EGFP, [Ca2+]i elevation with
ionomycin or thapsigargin caused gravin redistribution from the cell periphery to the
cytosol in as little as 60 seconds. ATP treatment also triggered gravin redistribution
through receptor-mediated pathways involving both [Ca2+]i and PKC. Gravin
redistribution in response to ionomycin, thapsigargin, and ATP each triggered the gravindependent loss of PKA localization at the cell periphery. In addition, we also found that a
fourth putative calmodulin binding domain, which we call CB4 (a.a. 669-693), is
essential for localization of gravin to the cell periphery. Either deletion of the CB4

xv

domain or mutation of a calmodulin-binding consensus sequence within the CB4 domain
disrupted the membrane localization of gravin.
Next, we measured the impact of exogenous gravin-V5/His expression on
compartmentalized PKA activity using the PKA FRET biosensor AKAR3. Expression of
gravin-V5/His in AN3 CA cells, which lack endogenous gravin, caused an increase in
forskolin-stimulated PKA activity at the plasma membrane when compared to control
cells lacking gravin. Under these conditions, gravin also decreased PKA activity in the
cytosol. Gravin’s impact on subcellular PKA activity required both interaction with PKA
and localization at the cell periphery. Pre-treatment with the [Ca2+]i elevating agent
thapsigargin caused gravin redistribution and inhibited gravin-mediated elevation of PKA
activity the plasma membrane. These results support the hypothesis that gravin mediates
crosstalk between Ca2+-dependent and PKA-dependent signaling pathways.
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CHAPTER I
INTRODUCTION
A-Kinase Anchoring Proteins
The most fascinating characteristic of the cell is its ability to transduce
extracellular inputs into very specific outputs through complicated networks of signaling
proteins, molecules and ions. Intracellular signal transduction is fundamental to cellular
homeostasis and relies on precise physical interactions between proteins within an inputdirected signaling cascade. Many signaling proteins have a range of downstream targets
but no intrinsic ability to specify which of these targets are appropriate for a given input.
How do cells facilitate the specificity of signaling proteins? In part, the answer to this
question lies in the spatial positioning of signaling proteins in close proximity to specific
downstream effectors (Good, Zalatan, & Lim, 2011). A prototypical example of this is
found in the A-Kinase Anchoring Proteins, or AKAPs, a specialized family of over 70
scaffolds which play an important role organizing intracellular signaling networks
(Welch, Jones, & Scott, 2010).
AKAPs share two common structural characteristics: the ability to bind cAMPdependent Protein Kinase A (PKA) and the ability to localize within a specific
subcellular compartment. This localization “anchors” PKA in proximity to downstream
substrates for phosphorylation, thereby providing spatial and temporal specificity to
PKA-dependent signaling. PKA is a holoenzyme consisting of two catalytic (C) subunits
that are bound to two regulatory (R) subunits. AKAPs bind to the R subunit through a
1

conserved amphipathic helical domain, and upon activation by 3’-5’-cyclic adenosine
monophosphate (cAMP), the R subunit releases the C subunit to phosphorylate substrate
proteins nearby. The interaction of AKAPs with PKA is critical to many PKA-dependent
processes. In fact, studies now show that disrupting AKAP-PKA interaction can have the
same effect as inhibiting PKA directly (Nijholt et al., 2008; Schillace et al., 2009; Y.
Wang, Chen, Chen, & Xu, 2006). Since PKA is predicted in Homo sapiens to
phosphorylate over 900 sites on 240 different proteins (Gao, Jin, Ren, Yao, & Xue,
2008), the apparent control of AKAPs over PKA signaling gives AKAPs a powerful role
in regulating many cellular functions.
Equally important to AKAP function is the subcellular localization motif, which
is varied among AKAPs and targets each to a specific compartment. These include the
plasma membrane, mitochondria, Golgi apparatus, nuclear envelope, and cytosolic
vesicles, or to other localized proteins such as cytoskeletal proteins, centrosomal proteins,
or membrane receptors (Wong & Scott, 2004). AKAPs target PKA to these subcellular
compartments and facilitate the PKA-dependent phosphorylation of substrates in close
spatial proximity within these compartments. In addition, many AKAPs bind not only
PKA, but a host of other kinases, phosphatases, and regulatory enzymes that may act
independently or within an anchored multiprotein signaling complex in which substrates
and downstream effectors are bound to the a single AKAP. One example of an anchored
multiprotein signaling complex is found in AKAPs that bind both PKA and
phosphodiesterase type 4D (PDE4D), a PKA substrate that hydrolyzes cAMP to
adenosine monophosphate. Upon elevation of [cAMP], activated PKA phosphorylates
PDE4D to enhance PDE4D activity. As a result, PDE4D activity causes the rapid
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decrease in [cAMP], forming a negative feedback loop for [cAMP] elevation (Dodge et
al., 2001).
Given the important physiological relevance of PKA signaling, the apparent
control of PKA signaling by AKAPs, and the multitude of other enzymes bound to
AKAPs, we expect the study of AKAPs will yield a robust understanding of cellular
signaling in many cell and tissue contexts. The subject of this dissertation is the AKAP
gravin, which is implicated to have a broad range of physiological roles. By examining
the molecular signaling events in which gravin participates, my hope is to gain
mechanistic insights into gravin’s role in health and disease.
Gravin
Gravin, a 300kD AKAP, was discovered in the early 1990s while screening an
endothelial expression library with serum from a patient with myasthenia gravis (Gordon
et al., 1992). Subsequently, gravin expression has been detected in a variety of cells and
tissues and has been implicated to play a role in cancer, vascular biology, cardiac
function, learning and memory, inflammation, and tissue injury. However, the
mechanism(s) behind these diverse roles are poorly understood, and this lack of
knowledge is a serious barrier to potential therapeutic applications. Three isoforms of
gravin (α, β, and γ) seem to vary in subcellular localization, but the canonical α-isoform
is targeted to the plasma membrane where it is thought to facilitate not only PKAdependent signaling, but signaling involving additional binding partners such as other
kinases, regulatory enzymes, and β2-adrenregic receptor. Although gravin localizes PKA
and other enzymes to the plasma membrane, it is known to undergo redistribution away
from the plasma membrane in response to either elevation of intracellular calcium
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concentration ([Ca2+]i) or upon activation of protein kinase C (PKC). Because AKAPs
function in the spatial and temporal positioning of signaling enzymes, the redistribution
of gravin may have a profound impact on how enzymes that bind to gravin, such as PKA,
interact with specific downstream effectors. By changing its distribution in subcellular
space, we postulate that gravin facilitates a crosstalk mechanism in which Ca2+ elevation
and/or PKC activation can alter interaction of enzymes bound to gravin with their
respective downstream targets.
Orthologues, Isoforms, and Nomenclature
Within the human genome, gravin is located on the q24-25.2 locus of
chromosome 6 and contains six exons that are differentially spliced into three distinct
isoforms, each with its own promoter (Streb, Kitchen, Gelman, & Miano, 2004; Streb &
Miano, 2005). All three isoforms share exons 5 and 6, which makes up ~95% of the
amino acid sequence. The canonical isoform, gravin-α, is a 1782 amino acid protein
product with its N-terminal sequence derived from exons 1 and 2. These exons comprise
an 88 amino acid region unique to gravin-α which contains an N-myristoylation sequence
and a Src binding (PXXP) domain. The -β isoform (1682 amino acids) and the –γ isoform
(1677 amino acids) contain N-termini from exons 3 and 4, respectively. Gravin-β and -γ
lack these 88 amino acids, but still retain three polybasic domains (PB1-3) important for
localization at the plasma membrane.
Gravin is expressed in many species including humans (Gordon et al., 1992),
baboons (Grove, Bowditch, Gordon, del Zoppo, & Ginsberg, 1994), rodents (Frankfort &
Gelman, 1995), zebrafish (Weiser, Pyati, & Kimelman, 2007) and Xenopus (Klingbeil,
Frazzetto, & Bouwmeester, 2001). Human gravin was discovered in an endothelial cell
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expression library screened with serum from a patient with myasthenia gravis, and was
named gravin accordingly. (Gordon et al., 1992). Gravin was later called AKAP250
based on sequencing and biochemical data which revealed it to be an A-Kinase
Anchoring Protein that aligned with a 250 kD marker on polyacrylamide gel (Nauert,
Klauck, Langeberg, & Scott, 1997). The gravin gene was named AKAP12 by the Hugo
Gene Nomenclature Committee (HGNC) and has also been used as an identifier of the
protein product (Xia, Unger, Miller, Nelson, & Gelman, 2001). Gelman and colleagues
discovered rodent gravin as a target of PKC phosphorylation which was suppressed in
Src-transformed rat fibroblasts (Lin, Tombler, Nelson, Ross, & Gelman, 1996a). On this
basis, it was named SSeCKS, or Src-Suppressed C-Kinase Substrate. The orthologous
relationship between SSeCKS and gravin was not realized initially, but they in fact share
83% sequence identity within the first 1000 residues and <20% over the remaining Cterminus. Upon this realization, some authors sought to adapt the nomenclature using
awkward names like “SSeCKS/gravin/AKAP12”, but in recent years there is growing
consensus for use of the name “gravin” across species. For example, knockdown mice
and zebrafish studies have used the word gravin to name the gene target, which is
especially helpful if multiple species are under investigation within a single study (for
examples of this, see D. Canton et al., 2012; Guillory et al., 2013; Havekes et al., 2012;
Isoldi, Provencio, & Castrucci, 2010; Weiser et al., 2007). Therefore, for this dissertation
I will use the word “gravin” as the overlying nomenclature when referring to previous
studies and indicate the species as needed. If I give no species specification, my use of
the name “gravin” will be in reference to the alpha isoform that is expressed in humans.

5

Expression in Cells and Tissues
Gravin expression is specific to certain cells and tissues, and this distribution
seems to be consistent across various studies. In general, high expression of gravin is
seen in nervous tissue, connective tissue, heart, smooth muscle, and gonads, while low or
restricted expression is found in endothelium and other epithelia. Gravin is also
differentially expressed during development. The following section will briefly outline
each of these areas.
Nervous Tissue
Regions of the cerebral and cerebellar cortices show distinct cellular expression of
gravin, with some reports of Purkinje cell expression and high expression in cells the
molecular and granular layer of the cerebellum (Gelman, Tombler, & Vargas, 2000;
Grove et al., 1994; Siegel, Grove, & Carr, 2002). In the hippocampus, gravin is expressed
in the dentate gyrus as well as CA1 and CA3 regions (Havekes et al., 2012). Astrocytes
also highly express gravin in an oxygen-sensitive manner (Lee et al., 2003). Siegel et al.
(2002) additionally showed gravin expression in smaller-sized cell bodies of dorsal root
ganglia and dorsal horn axons throughout the spinal cord, possibly indicating a role for
gravin in pain sensation.
Heart and Vasculature
Gravin expression is found in cardiomyocytes but not in cardiac endothelium
(Guillory et al., 2013). In general, endothelial cells show a restricted expression pattern of
gravin in vivo. Nearly all endothelial cells show no gravin expression, with the exception
of hepatic sinusoids and intestinal lacteals (Gelman et al., 2000; Grove et al., 1994; RungRuangkijkrai, Fujikura, Kitamura, Saito, & Iwanaga, 2004). Gravin is expressed in
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microvascular endothelial cells in culture (Weissmuller et al., 2014). In addition, gravin is
expressed in human umbilical vein endothelial cells (HUVECs) in a cell densitydependent manner (Roy, Schott, and Grove, in preparation), which suggests that gravin
may be important in vascular homeostasis. Smooth muscle cells also express gravin in
various locations throughout the body, one of which is in the vasculature (Coats et al.,
2000; Gelman et al., 2000; Grove et al., 1994; Horvat et al., 2012).
Epithelium
Like endothelium, most other epithelial cells do not express gravin with a few
notable exceptions. Gelman et al. (2000) reported gravin expression in mouse jejunal
epithelium, columnar epithelium of lung bronchioles, and certain portions of renal
epithelium. Interestingly, the parietal layer of Bowman’s capsule in the renal glomerulus
has exceptionally high levels of gravin expression (Gelman et al., 2000; Grove et al.,
1994).
Connective Tissue
Several reports show high gravin labeling in connective tissues both in adulthood
and during development. Organ capsules have consistently high expression levels, as
does the mesentery and lamina propria of the gut. The principle cell showing high
expression in these tissues is the fibroblast, but gravin expression is also reported in
osteoclasts and chondrocytes (Gelman et al., 2000; Grove et al., 1994).
Gonads
High levels of gravin are found in both the testes and the ovaries. The testis is the
only reported location for gravin-γ, but gravin-α is also expressed in the testis (Streb et
al., 2004). Another report shows that Sertoli cells express gravin, as well as spermatids
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(Erlichman, Gutierrez-Juarez, Zucker, Mei, & Orr, 1999). Interestingly, delayed fertility
was reported in one particular line of gravin knockdown mice (Akakura, Huang, Nelson,
Foster, & Gelman, 2008) and may indicate the possibility that gravin is important for
germ cell maturation. In the female mouse, gravin is also highly expressed in the ovaries
(Lin, Nelson, & Gelman, 2000).
Miscellaneous
Within the kidney, in addition to the various epithelial cells discussed previously,
high levels of gravin are found in mesangial cells of the glomerulus (Gelman et al., 2000;
Grove et al., 1994; Nelson, Moissoglu, Vargas Jr, Klotman, & Gelman, 1999). Not far
away from this location, cells of the adrenal medulla also express high levels of gravin
(Grove et al., 1994). In the liver, gravin expression is reported not only in hepatic
sinusoid endothelium, but also in hepatic stellate cells (Gelman et al., 2000; Grove et al.,
1994; Jiang et al., 2008; T. You et al., 2013)
Expression during Development
During mouse development, gravin is highly expressed in mesenchyme and
around neural precursors like the neural tube, neural crest, and in neural crest-derived
spinal primordia. Gravin is also expressed in dorsal/ventral surfaces of limb buds and in
other organs as development progresses (Gelman et al., 2000). In Xenopus laevis,
Klingbeil et al. (2001) show that gravin is differentially expressed during development.
Expression of Xenopus gravin begins stage 10 and continues throughout development
with peak expression seen at stages 11-12. During gastrulation, gravin is distributed in
posterior mesodermal cells on the dorsal lip of the blastopore (the Spemann organizer).
As gastrulation progresses, this labeling pattern progressively distributes downward
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around the blastopore circumference. During Xenopus neurulation, gravin is expressed in
the forebrain and on two bilateral neuroectodermal stripes at the midbrain/hindbrain
boundary. Gravin is also found in the notochord, spinal cord, and in mandibular neural
crest cells. At later stages of development, Xenopus embryos show predominant labeling
in the heart and notochord (Klingbeil et al., 2001). The role of gravin in Xenopus
development is completely unknown, but an interesting study by Weiser et al. (2007)
suggests a critical role for gravin during gastrulation in zebrafish (Danio rerio). In this
study, antisense morpholino knockdown of gravin dramatically reduced anterior-posterior
axis extension by blocking the extension of paraxial mesodermal cells lateral to the
notochord. This resulted in defective formation of the heart, pancreas, and liver.
Role of Gravin in Health and Disease
Many studies suggest that gravin plays a broad physiological role in health and
disease. The majority of these studies are expression-based, and the lack of mechanistic
insight provides a serious barrier to therapeutic application. Nonetheless, the apparent
role of gravin in health and disease is quite impressive, not only in terms of the broadness
of its impact, but also the importance that these physiological processes represent in
human health. The following section will highlight what is known about gravin’s role in
health and disease states.
Regulation of Gravin Expression in Cancer
Oncogenic kinases v-Src and v-Jun induce tumorigenic phenotypes marked by
mitogenic dysregulation and cytoskeletal remodeling in rodent fibroblasts. Early on,
Gelman and colleagues discovered that Src- and Jun-induced transformation of these
cells was accompanied by suppressed gravin expression (Frankfort & Gelman, 1995; Lin
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et al., 1996a; Nelson & Gelman, 1997). Importantly, the re-expression of exogenous
gravin in these transformed rat fibroblasts inhibited mitogenic dysregulation by reducing
soft-agar growth and dramatically reducing proliferation rate. (Cohen, Waha, Gelman, &
Vogt, 2001; Lin & Gelman, 1997). Subsequently, downregulation of gravin in cancer
tissues has been widely reported. For example, microarray studies show suppressed
gravin expression in cancerous lung (Tessema et al., 2008), thyroid (Wasenius et al.,
2003), colon (Yildirim et al., 2013), and liver (Goeppert et al., 2010). Other studies show
that gravin is suppressed in cancers derived from stomach (M. C. Choi et al., 2004),
pancreas (Cao et al., 2004; Mardin et al., 2010), breast (Vaidya & Welch, 2007), skin
(Bonazzi, Irwin, & Hayward, 2009), blood (Mostafa, Yahia, Abd El Messih, El-Sisy, &
El Ghannam, 2013; Yildirim et al., 2007), and grade IV astrocytoma (Goeppert et al.,
2013). These studies further reveal that the gravin is often silenced by epigenetic
mechanisms in many types of cancer, and re-expression can be achieved by treatment
with the demethylating agent 5’-Aza-dC or with the histone deacetylase inhibitor TSA.
Gravin’s gene locus on chromosome six is considered to be a major hotspot for
deletion in cancers, particularly advanced prostate cancer. Indeed, gravin is readily
detected in secretory epithelium and the surrounding mesenchyme of normal prostate
tissue, but is silenced in prostate cancer biopsies and a variety of prostate cancer cell lines
(Xia et al., 2001). Subsequently, much information has been gained from a model system
which uses the forced re-expression of exogenous gravin in MatLyLu prostate cancer cell
lines, which are gravin-deficient. Forced gravin expression in these cells inhibits
proliferation, soft agar growth, Boyden chamber chemotaxis, and matrigel invasion (Su,
Bu, Engelberg, & Gelman, 2010; Xia et al., 2001). Injection of these cells into nude mice
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further revealed that gravin re-expression inhibits tumorigenesis, metastasis, and
angiogenesis in subcutaneous tumors through the downregulation of VEGF expression
(Su, Zheng, Vaughan, Bu, & Gelman, 2006). Moreover, prostate tissue from gravin
knockout mice showed hyperplasia in the anterior and ventral lobes which was
concurrent with increased expression of markers for proliferation and apoptosis (Akakura
et al., 2008). Mechanistic insights from these expression studies strongly suggest that
gravin interacts with PKC, MEK, ERK, MMP-2, and E-cadherin pathways in prostate
cancer. However, the precise nature of gravin’s interaction with these signaling mediators
in cancer progression is poorly understood.
Regulation of β2-adrenergic Receptor Sensitivity
Gravin’s influence over β2-adrenergic receptor (β2AR) signaling has been studied
extensively in the context of receptor resensitization (Reviewed by Malbon, Tao, &
Wang, 2004). As a result, in vivo studies have now investigated this interplay in the
hippocampus and the heart. In hippocampal brain slices of gravin-knock down mice,
Havekes et al. (2012) demonstrated that β2AR mediated synaptic plasticity is altered at
CA1 synapses. A variety of behavioral tests revealed that gravin knock-down mice
displayed impairments in fear-conditioned long-term memory formation, and this
corresponded with a reduction in phosphorylation of β2AR and ERK1/2 (Havekes et al.,
2012). This study correlates well with the notion that gravin regulates β2AR sensitivity
and sets the stage for future studies to investigate the intracellular dynamics between
these two proteins in hippocampal learning and memory.
In the heart, Guillory et al. (2013) used echocardiography in a different mouse
model to show that gravin knockdown enhances cardiac contractility under both basal
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conditions and when treated with isoproterenol, a β2AR agonist. Cultured
cardiomyocytes from these mice had significantly altered calcium dynamics as well,
implying that gravin may regulate L-type calcium channels or sarcoplasmic reticulum
ryanodine receptors, both of which are phosphorylated by PKA. Interestingly, gravin
knockdown caused a dramatic increase in phosphodiesterase activity in response to
isoproterenol treatment, despite the fact that cellular cAMP levels and PDE4D3/5
expression were unchanged (Guillory et al., 2013). Although this study raises many
unanswered questions regarding the role of gravin in cardiac physiology, it is clearly
linked at least in part to β2AR signaling and will be an area of great interest in future
research.
Regulation of Vascular Endothelial Function
Grove and Bruchey (2001) reported that gravin binds both PKA and PKC in
human umbilical vein endothelial cells (HUVECs) and is distributed at the cell periphery
independent of cytoskeletal proteins (Grove & Bruchey, 2001). Data from our lab have
further revealed that subconfluent HUVECs readily express gravin, but confluent
monolayers do not. In fact, scratch wounded confluent HUVEC monolayers showed
elevated gravin expression at the wound edge, and gravin knockdown under these
conditions slowed the rate of wound closure (Roy, Schott, and Grove; in preparation).
This would imply that gravin enhances cellular migration, but the role of gravin in
endothelial cell migration may be more complicated. For example, Turtoi et al (2010)
suggested that HDAC7 knockdown in HUVECs leads to gravin overexpression and the
inhibition of cellular migration (Turtoi et al., 2012). It is clear that gravin plays a role in
cell migration, but future studies will be required to understand these differential results.
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In addition to regulating endothelial cell migration, gravin is also shown to
regulate endothelial barrier permeability. In human microvascular endothelial cells
(HMEC), gravin inhibited the formation of endothelial tubules, and in response to GPCR
agonists, gravin supported endothelial barrier strength (Weissmuller et al., 2014). In
zebrafish embryos, gravin was also linked to the enhancement of endothelial cell-cell
contacts (Kwon et al., 2012). Conversely, You et al (2010) showed that gravin may
promote endothelial permeability in response to inflammatory cytokines. (Q. H. You,
Sun, Wang, Chen, & Luo, 2010).
Gravin may also regulate endothelial cell function through supporting cells that
associate with the vasculature. For example, gravin regulates vascular endothelial
function indirectly through gravin-expressing astrocytes at the blood-brain barrier. A
study by Lee et al. (2003) showed that gravin expression in astrocytes causes VEGF
downregulation, and that conditioned medium from gravin-overexpressing astrocytes
suppressed endothelial cell angiogenesis. In addition, conditioned medium from gravinoverexpressing astrocytes also stimulated the increased expression of tight junction
proteins in endothelial cells, supporting cell-cell contact and resisting endothelial
permeability (Lee et al., 2003). These results were confirmed in a similar study using
gravin-overexpressing astrocytes (Y. K. Choi & Kim, 2008).
Regulation of Gravin Expression by Inflammatory Mediators
Many inflammatory mediators have been shown to increase gravin expression,
but the physiological impact of this is poorly understood. Lipopolysaccharide (LPS)
induces gravin upregulation in a variety of adherent cells and tissue models (Cheng et al.,
2007; Kitamura et al., 2002; M. Yan et al., 2007; M. Yan et al., 2014). Gravin
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upregulation seems to support LPS-mediated production of TNF-α, nitric oxide, iNOS,
and the phosphorylation of ERK, p38, and JNK. (X. Li et al., 2010; Shao et al., 2011;
Sun, Cheng, Liu, Shen, et al., 2007; P. Wang et al., 2010). Gravin was also shown to be
upregulated in response to TNF-α (Pagnotta et al., 2013; M. Yan et al., 2007; Q. H. You
et al., 2010), TGF-β, and interleukins 1β and 17F (Q. h You, Sun, Wang, Shen, & Wang,
2010).
Role of Gravin in Cellular Signaling
It is likely that gravin mediates its broad physiological impact by binding to a
variety of signaling enzymes and targeting them to specific subcellular compartments.
The following section will overview the mechanistic role of gravin in cells by outlining
its molecular structure, binding partners, and intracellular localization dynamics.
Molecular Structure and Subcellular Distribution
Gravin has a predicted rod-like structure and binding domains for many different
molecules (Lin et al., 1996a). Four domains are responsible for plasma membrane
localization and include a putative N-terminal myristoylation site and three polybasic
domains located at residues 171–191, 296–316 and 507–536. Whereas the putative
myristoyl group is added posttranslationally and serves as an N-terminal lipid anchor,
gravin’s polybasic domains are believed to electrostatically adhere to acidic
phospholipids of the plasma membrane (Malbon, Tao, Shumay, & Wang, 2004; Resh,
1999). The polybasic domains also show additional binding affinity for cholesterol, and
along with the N-myristoylation site support the notion that gravin may localize
preferentially to lipid rafts of the plasma membrane (M. C. Choi, Lee, Kim, Lee, et al.,
2008; Su et al., 2013). The relative contribution of each of these domains to plasma
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membrane localization is somewhat complex. Gravin mutants lacking the myristoylation
site have seemingly normal localization at the cell periphery, as do gravin mutants that
lack the polybasic domains but retain the myristoylation site (Tao, Shumay, McLaughlin,
Wang, & Malbon, 2006; X. Yan, Walkiewicz, Carlson, Leiphon, & Grove, 2009). This
means that the myristoylation site or all three polybasic domains are each sufficient, but
not necessary for membrane localization. The sufficiency of the myristoylation site for
membrane localization is surprising given the relatively weak binding energy provided by
myristoyl groups – other models suggest that membrane binding due to N-myristoylation
requires other membrane-bound binding regions for support (Resh, 1999). The mechanics
of gravin membrane localization is important because it plays a central role in regulating
the interaction of gravin-anchored enzymes with potential downstream substrates.
Gravin Binds to Protein Kinase A
Several studies suggest that gravin anchors a host of signaling enzymes. Gravin
binds to PKA RIIα through C-terminal amphipathic helical domain, a domain which has
been shown in other AKAPs to interact with the docking domain (D/D) of RIIα on the
hydrophobic pocket of AKAP amphipathic helix (Gold et al., 2006; Nauert et al., 1997).
Gravin-PKA interaction directs PKA RII to the cell periphery and is required for the
phosphorylation of downstream PKA substrates. Yan et al. (2009) showed that cells
expressing both gravin-EGFP and PKA RII-ECFP co-distribute at the cell periphery, and
PKA RII-ECFP does not distribute at the cell periphery in cells co-expressing a gravin
mutant lacking the PKA binding domain (X. Yan et al., 2009). It is likely that gravin
targets PKA to the plasma membrane for phosphorylation of PKA substrates at the
plasma membrane. Two known downstream substrates are β2-adrenergic receptor
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(β2AR) and gravin itself. Tao et al. (2003) showed that PKA phosphorylates gravin and
thereby enhances gravin’s association with β2AR, and this phosphorylation does not
occur in gravin mutants missing the PKA binding domain. In addition, PKA that is
anchored to gravin phosphorylates β2AR and is required for receptor resensitization
following isoproterenol induced desensitization (Tao, Wang, & Malbon, 2003).
Phosphorylation of additional PKA substrates at the membrane are likely to be regulated
by gravin-PKA interaction, but this has not been explored to date.
Gravin Binds to β2-Adrenergic Receptor
Malbon and colleagues have reported extensively on gravin’s interaction with
β2AR, a G protein-coupled receptor that activates PKA by stimulating cAMP production
(G. F. Fan, E. Shumay, H. Y. Wang, & C. C. Malbon, 2001; F. Lin, H. Y. Wang, & C. C.
Malbon, 2000; Malbon, Tao, & Wang, 2004; Shih, Lin, Scott, Wang, & Malbon, 1999b;
Tao et al., 2006; Tao et al., 2003; Tao, Wang, & Malbon, 2007). Gravin-β2AR binding
has been demonstrated in various pull-down assays and is reported to occur between
residues 652-938 of gravin and the C-terminal cytoplasmic tail of β2AR (F. Lin, H. Y.
Wang, et al., 2000; Shih et al., 1999b; Tao et al., 2003). A thorough study by Tao et al
(2003) showed that upon isoproterenol treatment, gravin is phosphorylated on serines
696, 697, 698, and 772 by gravin-anchored PKA, and this phosphorylation strengthens
the association of gravin with β2AR. Additionally, gravin-β2AR interaction is required
for receptor resensitization following isoproterenol-mediated receptor desensitization
(Tao et al., 2003). Knockdown of gravin also prevents the association of β2AR with other
molecules like β-arrestin, GRK2, and clathrin, but whether this is dependent on gravinβ2AR interaction has not been demonstrated (F. Lin, H. Y. Wang, et al., 2000). It is
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likely that gravin plays a major role not only in regulating β2AR dynamics, but also in
influencing other downstream PKA substrates following receptor activation.
Gravin Binds to Protein Kinase C
Gravin has been shown to bind several PKC isoforms in cultured human and
rodent cell lines (Grove & Bruchey, 2001; Guo, Gao, Rothschild, Su, & Gelman, 2011;
Lin et al., 1996a; Nelson, Moissoglu, Vargas Jr, et al., 1999; Piontek & Brandt, 2003).
Gravin-PKC interaction has been reported to suppress ERK1/2 phosphorylation (Su et al.,
2010) and also suppress PKC activity itself (Guo et al., 2011), and facilitate phorbol
ester-induced cytoskeletal remodeling (Guo et al., 2011). Activation of PKC by phorbol
ester triggers the redistribution of gravin to juxtanuclear vesicles and is thought to occur
through PKC phosphorylation of gravin at the membrane-binding polybasic domains (Lin
et al., 1996a; Malbon, Tao, Shumay, et al., 2004; Nelson, Moissoglu, Vargas Jr, et al.,
1999; Piontek & Brandt, 2003; X. Yan et al., 2009). Interestingly, Yan et al. (2009)
demonstrated that a mutant gravin-EGFP construct lacking the polybasic domains still
underwent redistribution to a juxtanuclear compartment upon PKC activation, which
suggests (A) that the mechanism of PKC-mediated gravin redistribution is more complex
than phosphorylation of the polybasic domains, and (B) that PKC-mediated gravin
redistribution may occur independent of gravin-PKC interaction since this mutant also
lacked the putative PKC-binding domain. Interestingly, PKC activation by phorbol ester
also causes the upregulation of gravin expression in cultured human erythroleukemia
cells (HEL), which do not express gravin under basal conditions (Gordon et al., 1992;
Grove et al., 1994; Nauert et al., 1997). Given the findings that PKC is suppressed when
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bound to gravin, it would be interesting to investigate whether this supports a negative
feedback loop in PKC-mediated gravin expression levels.
Gravin Binds to Src
Gravin binds to Src within the first fifty amino acids of gravin’s N-terminus in
human epidermal carcinoma cells, and this interaction is reported to enhance Src activity.
It is also required for β2-adrenergic receptor resensitization following isoproterenol
induced desensitization (Tao et al., 2007). A more recent study in mouse pancreatic
carcinoma cells showed that gravin may also bind to Src at polybasic domain 1, and this
interaction strengthens cell adhesion by sequestering Src away from focal adhesion
plaques to lipid rafts (Su et al., 2013).
Gravin Binds to Polo-Like Kinase 1
A recent study by Canton et al (2012) elegantly showed that gravin is
phosphorylated by CDK1 on threonine 766 during mitosis, and this stimulates the
interaction of gravin with Polo-like kinase 1, a mitotic kinase. During mitosis, phosphogravin and Plk1 congregate alongside nuclear DNA during prophase and at the mitotic
spindle during metaphase, but segregate once the cell reaches anaphase. Since gravin
knockdown was shown to impact the fidelity of mitotic progression, the authors proposed
that this gravin-Plk1 interaction may in part facilitate gravin’s role in regulating cell cycle
events.
Gravin Binds to Cyclin D1
Gravin has been demonstrated to interact with cyclin D1 in both cultured rodent
cells and in mouse parietal epithelial cells of Bowman’s capsule (Burnworth et al., 2012;
Lin & Gelman, 2002; Yamamoto, Tamakawa, Yoshie, Yaginuma, & Ogawa, 2006). This
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interaction occurs through two cyclin binding “CY” motifs between residues 500-517 of
rodent gravin and sequesters cyclin D1 away from the nucleus. Interestingly, PKC
phosphorylates gravin and inhibits gravin-cyclin interaction, stimulating cyclin D1 to
localize back into the nucleus (Burnworth et al., 2012; X. Lin et al., 2000). The authors of
these studies propose that gravin regulates G1-S stalling through its dynamic interaction
with cyclin D1.
Gravin Binds to Calmodulin
Two reports highlight the interaction of gravin with calmodulin. In rodent gravin,
Lin and Gelman (2002) identified four regions with “1-5-10” consensus sequences for
calmodulin binding: two of these sequences (residues 289-297 and 502-511) fall within
polybasic domains 2 and 3, and the other two are located downstream between residues
664-673 and 851-860, respectively. Calmodulin bound to peptides containing these four
regions in a calcium-dependent manner and was inhibited by PKC activity (Lin &
Gelman, 2002). A later study in human gravin also revealed four calmodulin binding
domains with some variation to that in rodents: calmodulin bound to polybasic domains
1, 2, and 3 (residues 171-187, 297-317, and 510-536), and a fourth downstream region
containing a 1-5-10 motif (residues 670-694) that corresponds to the third calmodulin
binding domain of rodent gravin (Tao et al., 2006). It is noteworthy that human gravin
lacks the last calmodulin binding motif found in rodent gravin (851-860), and the impact
of this is completely unknown. Additionally, it’s interesting that human gravin contains
only two “1-5-10” motifs at the second and fourth calmodulin binding domain, whereas
rodent gravin contains four of these motifs. This suggests that human gravin binds
calmodulin at each of these sites with differential affinity, as evidenced in the paper by
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Tao et al. (2006) where polybasic domain 2 of human gravin showed greater affinity for
calmodulin than did polybasic domains 1 and 3. The affinity of calmodulin for the fourth
calmodulin binding domain of human gravin was not explored in Tao’s study. The impact
of gravin-calmodulin interaction is thought to promote the dissociation of gravin away
from the plasma membrane especially through calmodulin interaction with the polybasic
domains (Malbon, Tao, Shumay, et al., 2004). Tao et al. (2006) demonstrated that
peptides corresponding to polybasic domains 1, 2, and 3 bound to lipid vesicles in silico,
and this binding was reversed by calmodulin protein in a calcium-dependent manner.
This mechanism has also been modeled in other proteins with polybasic domains similar
to gravin (McLaughlin, Hangyas-Mihalyne, Zaitseva, & Golebiewska, 2005).
Gravin Binds to Phosphodiesterase Type 4D
Gravin’s interaction with phosphodiesterase type 4D (PDE4D) has been
demonstrated via pull-down both in human embryonic kidney (HEK293) and cultured rat
aortic smooth muscle cells (Raymond, Carter, Ward, & Maurice, 2009; D. Willoughby,
W. Wong, J. Schaack, J. D. Scott, & D. M. F. Cooper, 2006b). Willoughby et al. (2006)
showed that either inhibition of PKA or disruption of PKA-AKAP interaction inhibited
PDE-dependent cAMP hydrolysis at the plasma membrane. Gravin knockdown also
inhibited plasma membrane cAMP hydrolysis. Based on these data, gravin was proposed
to regulate compartmentalized [cAMP] dynamics by binding to PDE4D and targeting it
to the plasma membrane. Importantly, the binding domain for PDE4D on gravin has not
been determined, nor has the importance of gravin-anchored PKA been elucidated in
gravin’s regulation of [cAMP].
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Gravin Undergoes Subcellular Redistribution in Response to Calcium
and/or PKC Activation.
Although gravin localizes to the plasma membrane under basal conditions, PKC
activation or elevation of [Ca2+]i triggers the redistribution of gravin away from the
plasma membrane. With PKC activation, gravin translocates to juxtanuclear vesicles (Lin
et al., 1996a; Nelson, Moissoglu, Vargas Jr, et al., 1999; X. Yan et al., 2009).
Juxtanuclear relocalization requires the myristoylation site, as mutant constructs missing
this N-terminal region translocate from the plasma membrane to the cytosol (X. Yan et
al., 2009). Although the mechanics of PKC-mediated gravin redistribution are not
completely understood, this event probably occurs through PKC phosphorylation of
gravin – which is a known PKC substrate – at sites that are important for membrane
localization. PKC phosphorylates gravin peptides containing the membrane-associated
polybasic domains (PB1-3) (Lin et al., 1996a), but alternative phosphorylation sites are
also likely to be important since a mutant gravin construct missing the polybasic domains
also underwent PKC-mediated redistribution from the plasma membrane to juxtanuclear
vesicles (X. Yan et al., 2009). Importantly, PKC-mediated gravin redistribution also
caused the relocalization of PKA from the plasma membrane to juxtanuclear vesicles,
suggesting that gravin facilitates cross-talk between PKC and PKA-dependent signaling
pathways.
Calcium elevation was shown by Tao et al. (2006) to cause the redistribution of
gravin away from the plasma membrane and into the cytoplasm. Like PKC, the
mechanics of calcium-mediated gravin redistribution are also poorly understood, but this
event is likely to involve the binding of calmodulin to the membrane-associated polybasic
domains (PB1-3). Calmodulin binds to gravin peptides corresponding to polybasic
21

domains 1, 2, and 3 in a calcium-dependent manner, releasing these peptides from
phospholipid vesicles in vitro. Calcium-mediated redistribution of gravin is proposed to
regulate β2-adrenergic receptor resensitization following agonist induced desensititzation,
but the impact of this event on enzymes bound to gravin is currently unknown. It is likely
that through this mechanism, gravin facilitates cross-talk between calcium and PKAdependent signaling pathways.
Research Goal and Hypothesis
Since gravin’s role in cellular signaling depends on the targeting of signaling
enzymes to discrete subcellular compartments, stimuli that regulate this subcellular
targeting of gravin are also likely to impact the signaling dynamics of a host of enzymes
bound to gravin. While it is known that intracellular calcium elevation triggers the
redistribution of gravin from the membrane to the cytosol, almost nothing is known about
the impact this event might have on signal transduction through signaling enzymes bound
to gravin. PKA binding to AKAPs is well characterized, which makes PKA an excellent
enzyme of study in investigating the impact of gravin dynamics on cell signaling.
Therefore, the goal of my research is to determine the impact of calcium mediated gravin
redistribution on PKA localization and PKA-dependent signaling.
The central hypothesis of my research is that gravin facilitates crosstalk between
calcium and PKA-dependent signaling pathways through subcellular redistribution. To
test this hypothesis, I used fluorescent gravin constructs to determine the effect of
pharmacological and receptor-mediated calcium elevation on gravin distribution and
gravin-directed PKA localization. In addition, I used mutant gravin constructs to explore
the role of gravin’s calmodulin binding domains in calcium-mediated gravin
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redistribution. Finally, I used the FRET-based PKA biosensor AKAR3 to determine the
impact of gravin on subcellular PKA activity under basal conditions and under conditions
which stimulate calcium-mediated gravin redistribution.
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CHAPTER II
METHODS AND MATERIALS
Cell Culture and Transfection
Two cell lines were used in this study: AN3 CA cells and HEC-1-A cells
(Manassas, VA, ATCC numbers: HTB-111, HTB-112 respectively). Both of these are
human adenocarcinoma-derived cell lines from the endometrium of the uterus. AN3 CA
cells were derived from a metastatic lesion in the lymph node of a 55 year old patient
with endometrial carcinoma. HEC-1-A cells were similarly derived from a 71 year old
patient with stage 1A endometrial carcinoma. While AN3 CA cells do not express gravin
endogenously, HEC-1-A cells do express gravin sporadically in small clusters of cells (X.
Yan et al., 2009).
Cells were maintained at 37°C with 5% CO2 in low glucose Dubecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and 100 units/ml
penicillin and 100ug/ml streptomycin. Growth medium was replaced three times each
week, and cells were split 1:25 upon reaching confluence. In experiments where cells
were transfected with expression vectors, cells were transfected two to three days after
seeding. To perform the transfection, cells were incubated in a transfection solution
containing 3µl/ml GeneJammer (Agilent) and 1µg/ml plasmid DNA for twenty-four
hours prior to microscopy. For experiments involving co-transfection with AKAR3 and
gravin-V5/His constructs, it was critical that cells found expressing AKAR3 also
expressed gravin-V5/His. To accomplish this, we found that a 1:3 molar ratio of
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AKAR3:gravin plasmid DNA in the transfection mixture yielded transfected cultures in
which roughly 90% of cells expressing AKAR3 also expressed gravin-V5/His (Fig. II-1).
Construction of Expression Vectors
Gravin-EGFP, (ΔPB1-3) gravin-EGFP, and PKA RII-ECFP vectors were initially
constructed as described in previous work (X. Yan et al., 2009). The current study used
several additional gravin constructs which were generated as follows.
Construction of (ΔPKA) Gravin-EYFP
and (ΔPKA) Gravin-V5/His
A gravin-EYFP construct lacking the PKA RII binding domain (nucleotides 46214662) termed “(ΔPKA) gravin-EYFP” was generated in three steps. First, a gravin
fragment containing the PKA binding domain (between AgeI/AgeI restriction sites) was
excised from full length gravin-EYFP and inserted into a pEYFP N1vector. The PKA
binding domain was then deleted from this fragment through a PCR based mutagenesis
approaching using a Phusion® site-directed mutagenesis kit (New England Biolabs,
product F-541) and forward primer and reverse primers
(5’ACAGCCGTTGACCAGTTTGTACGTACAGAA and
5’TTCCAAAATCCCATTTTCAGGCTCTAAATC respectively) flanking the PKA
binding domain. Finally, the mutated AgeI/AgeI gravin fragment generated in the new
vector was substituted for the wild type fragment in the original vector. Cloning of the
gravin fragment into an intermediate plasmid was necessary to due to difficulties
obtaining PCR products from full length gravin. The deletion of the PKA binding domain
was confirmed by sequence analysis. A gravin-V5/His construct missing the PKAbinding domain – termed “(ΔPKA) gravin-V5/His” – was generated by replacing a DNA
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fragment between two XbaI restriction sites of full-length gravin-V5/His with that of
(ΔPKA) gravin-EYFP.
Construction of (ΔPB1-3, CB4) Gravin-EGFP,
(ΔPB1-3+) Gravin-EGFP, and (ΔCB4) Gravin-EGFP
A gravin-EGFP vector lacking the three polybasic domains and the fourth
downstream putative calmodulin binding domain (nucleotides 125-2086) termed “(ΔPB13, CB4) gravin-EGFP” was generated by inserting a SacII site directly downstream of the
CB4 domain, and then removing nucleotides 125-2086 by SacII digestion
(Primers:5’GCAAGGAGAAGT[CCGCGG]CTGATGAGGAA ;
5’GGTGCGTCAAAGTCGGCTACGGGGGTGC; underlined nucleotides indicate the
position of the SacII site). A gravin-EGFP vector lacking the polybasic domains and all
nucleotides up to the beginning of the CB4 domain (Δ125-2011) termed “(ΔPB1-3+)
gravin-EGFP” was similarly generated by inserting a SacII restriction site directly
upstream of the CB4 domain, and removing nucleotides 125-2011 by SacII digestion
(Primers:5’CCAAAGC[CCGCGG]TGGATACCTCAGTATCT ;
5’GGTGCGTCAAAGTCGGCTACGGGGGTGC, mutagenic nucleotides underlined,
constructed SacII sequence in brackets). Finally, a gravin-EGFP construct lacking only
CB4 (Δ2005-2079) termed “(ΔCB4) gravin-EGFP” was generated by site-directed
mutagenesis (Phusion®, New England Biolabs, product F-541; forward primer
5’AGGTCGTCTTCTGATGAGGAAGGGGGACCA; reverse primer
5’TGGTTCTTCCGGCTTTGGCTCTTCAACGCT). Like the ΔPKA gravin construct
described above, the ΔCB4 mutation was done in an intermediate vector generated by
inserting a gravin fragment that included the CB4 domain (between AccI-SbfI) into
pmCherry N1. Following PCR mutagenesis and ligation of this intermediate vector, the
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mutated AccI-SbfI fragment missing the CB4 domain was substituted back into the
original gravin-EGFP vector. The deletion of the CB4 domain was subsequently
confirmed by restriction digest and sequence analysis.
Construction of (mutCB4) Gravin-EGFP
and (mutCB4) Gravin-V5/His
A gravin-EGFP construct with mutations in the CB4 domain – termed “(mutCB4)
gravin-EGFP” – was created by site-directed mutagenesis (Phusion®, New England
Biolabs, product F-541; forward primer 5’CATCTTGGGAAGCTGCAATTTGTGTG;
reverse primer 5’CTGAGGTATCCGCCTTTCGCTTTGGT; mutagenic nucleotides
underlined) resulting in the following mutationsV672A, V676A, and L681A. The
mutation indicated at the T position in the reverse primer is a silent mutation introduced
to optimize primer design. Site-directed mutagenesis of the CB4 region was performed
on the intermediate vector containing the gravin fragment described in the previous
paragraph. Following PCR mutagenesis and ligation of this intermediate vector, the
mutated Acc1-SbfI gravin fragment was substituted back in to full-length gravin-EGFP.
A gravin-V5/His construct with mutations in the in the CB4 domain – termed “(mutCB4)
gravin-V5/His” – was constructed by substituting a DNA fragment located between the
SacII and EcoRV restriction sites in the full-length gravin-V5/His with a corresponding
fragment from the (mutCB4) gravin-EGFP construct.
Construction of Lck-AKAR3
AKAR3 (A-Kinase Activity Reporter 3) is a live-cell biosensor that uses Förster’s
resonance energy transfer (FRET) to record changes in PKA activity in real time. Two of
the AKAR3 biosensors used in this study, AKAR3-NES and AKAR3-CAAX (also called
pmAKAR3), were kind gifts of Dr. Jin Zhang (Johns Hopkins) and were constructed as
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described previously (Allen & Zhang, 2006). The Lck-AKAR3 construct used in this
study was made in our lab by inserting a linker between the HindIII and BamHI
restriction sites of AKAR3-NES (Oligos:
5’AGCTTGCCACCATGGGCTGTGTCTGCAGCTCAAACCCTGAAAAG; 5’
GATCCTTTTCAGGGTTTGAGCTGCAGACACAGCCCATGGTGGCA).
Western Blotting
To obtain protein samples for Western blotting, AN3 CA cells were transfected in
T-25 flasks with 15 µL Genejammer (Aligent) and 5 μg of plasmid DNA per flask.
Twenty-four hours later, cells were harvested by scraping into 2 ml of ice-cold PBS (58
mM Na2HPO4, 17 mM NaH2PO4–H2O, 68 mM NaCl), pelleted by centrifugation, and
resuspended in 50 μl of lysis buffer (20 mM Tris base, 150 mM NaCl, 10 mM EDTA, 10
mM Benzamidine HCl, 1% (v/v) Triton X-100, 0.05% (v/v), Tween 20, 1 mM PMSF and
100 μg/ml leupeptin). Cell lysates were then run on 5% SDS-polyacrylamide gels and
transferred to nitrocellulose membranes by standard methods (Towbin, Staehelin, &
Gordon, 1979). Blots were then rinsed overnight in blocking buffer (1x PBS, 0.2% IBlockTM Reagent, 0.1% Tween®-20 Detergent) and probed using an antigravin
polyclonal antibody at a concentration of 1:5,000 for 60 minutes (Grove et al., 1994;
Grove & Bruchey, 2001). Blots were then labeled with an alkaline phosphatase conjugate
secondary antibody at a concentration of 1:100,000 for 60 minutes, and immunoreactive
bands were detected by incubating blots in CDB Star chemiluminescence reagent.
Immunofluorescence Labeling of Cultured Cells
For immunofluorescence labeling, cells were fixed in 3.7% paraformaldehyde in
PBS (150 mM NaCl, 4 mM Na/K phosphate buffer and 5 mM KCl) for 10 minutes and
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rinsed three times with PBS. Cells were then permeabilized with digitonin for 10
minutes, rinsed with PBS, and treated for 30 minutes with 5% normal goat serum at room
temperature to block non-specific binding of the antibody. Next, cells were treated with
an anti-gravin monoclonal mouse antibody at a concentration of 1:1000 for 60 minutes at
37° C, as previously described (X. Yan et al., 2009). Primary antibody labeling was
detected using CY3 conjugated donkey anti-mouse secondary antibody (Jackson
Immunoresearch, Inc., West Grove, PA) at a concentration of 1:200 for 60 minutes at 37°
C. Cells were mounted to glass slides using Pro-long® Gold antifade reagent with DAPI
(Life Technologies, P36935).
Epifluorescence Microscopy
Nikon TE300 Microscope
Experiments using quantitative imaging (calcium dynamics, gravin redistribution,
FRET microscopy) were done on a Nikon TE300 inverted microscope equipped with a
Hamamatsu camera, Ludl excitation and emission filter wheels, and a range filters for
fluorescence microscopy. This microscope uses a mercury lamp to generate fluorescence
excitation, which is passed through a combination of neutral density filters that control
the intensity of excitation from the mercury lamp. Neutral density filter settings were
optimized in each experiment to minimize photobleaching of fluorescent proteins.
Various excitation filters allowed only certain wavelengths of light to pass to the sample,
and these filters were located either in an automated excitation filter wheel or within one
of four filter cubes mounted on a slider underneath the objective lens carousel. Excitation
light passes through these excitation filters and is reflected up to the sample through and
objective lens by a dichroic mirror within one of the filter cubes. As the sample is
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excited, its emission fluorescence is passed back down through the objective lens, and the
same dichroic which reflected the excitation light up toward the sample also allows
emission fluorescence to pass back through the mirror where it is reflected either to the
ocular eyepieces or to a Hamamatsu CCD camera. (Fig. II-2) Emission filters allow only
certain wavelengths of emission fluorescence to reach the camera, and these emission
filters are situated either in the automated emission filter wheel or within the filter cubes.
Images were acquired using software called Micro-Manager, an open source
microscope controller developed by Vale and colleagues (Edelstein, Amodaj, Hoover,
Vale, & Stuurman, 2010). Micro-manager was used to control both the excitation and
emission filter wheels, the camera sensitivity (gain), and exposure time which was
controlled by a shutter in the excitation filter wheel. In a time-course experiment, a set
number images could be collected using multiple excitation/emission filter settings at a
specified time-interval. Image quantification was subsequently performed using ImageJ
software.
Calcium Imaging
Changes in [Ca2+]i were measured with Fura-2 using the ratio of fluorescence
intensity at excitation wavelengths of 340 and 380 nm. Cells on coverslips were
incubated at 37°C with 1 mg/ml Fura-2 AM (Invitrogen/Molecular Probes) for 30
minutes, rinsed with Standard Extracellular Solution (SES), and placed in an Attofluor
chamber heated to 37º C containing either SES (1.5 mM CaCl2 dihydrate, 145 mM NaCl,
5 mM KCl, 1 mM MgCl2 anhydrous, 10 mM glucose, 10 mM Hepes) or Ca2+ free SES
(145 mM NaCl, 5 mM KCl, 1 mM MgCl2 anhydrous, 10 mM glucose, 10 mM Hepes).
Images were obtained at 15 or 30 second intervals using a 40X Oil Plan Fluor objective
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lens (NA=1.3) mounted on a Nikon TE300 inverted microscope, and acquisition settings
were the same for each experiment (See Fig. II-3). Following acquisition, Fura-2
fluorescence images were background subtracted, and the ratio of Fura-2 fluorescence
intensity at 340 and 380 nm excitation wavelengths was measured for 10-20 cells per
coverslip at each time interval using ImageJ plugins for background subtraction and
ratiometric analysis (compiled by Tony Collins, McMaster Biophotonics Facility,
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton,
ON).
Quantification of Gravin Redistribution
Changes in the subcellular distribution of wild type or mutant gravin-EGFP
following agonist treatment were quantified by calculating the ratio of membrane to
cytosolic fluorescence intensity from images acquired at 15 or 30 second intervals using
the Nikon TE300 inverted microscope. Acquisition parameters were the same for each
experiment (See Fig. II-4). Following background subtraction in ImageJ, this ratio was
generated by measuring the fluorescence intensity profile along a line 1 pixel wide by 36
pixels long drawn at several points across the plasma membrane of cells expressing
gravin-EGFP (Fig. II-5A), calculating the mean fluorescence intensity of the four
brightest pixels at the peak of the intensity profile and dividing that by the mean
fluorescence intensity of the profile corresponding to the cytosolic portion of the cell
(Fig. II-5B,C). Preliminary analysis of cells in which the plasma membrane was labeled
with FM4-64 revealed that the plasma membrane region of the line profile was marked
by a sharp elevation in intensity roughly 4 pixels in width, while the region of the line
profile on the cytosolic side of these peak values provided a reasonable representation of
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the cytosolic fluorescence intensity. Points of measurement across the plasma membrane
were carefully selected to avoid non-fluorescent intracellular regions (e.g. nucleus) and
brightly fluorescent puncta within the cytosol. Loss of gravin-EGFP at the cell cortex
resulted in a decrease in membrane fluorescence intensity, an increase in cytosolic
fluorescence intensity, and a decrease in the ratio of membrane fluorescence against
cytosolic fluorescence (Fig II-5D). Ratios were normalized by dividing each ratio in the
time series by the mean ratio prior to agonist treatment. All analysis and quantification
was done on images in their native format (16-bit, 72 pixels/inch). For figures, cropped
greyscale images of gravin-EGFP were converted to 8-bit and resized using Adobe
Photoshop.
Quantification of Gravin Localization at the Cell Periphery
Assessment of gravin localization at the membrane was done by imaging cells at
predefined XY locations on coverslips, as set by a grid positioned on the microscope
stage. The center of each coverslip corresponded to the center of the grid, and images
were collected within nine predefined regions (Fig. II-6). Images were placed in random
order, and each cell was scored as “yes” or “no” for gravin localization at the cell
periphery in a blinded manner. The mean percentage of cells showing localized gravin at
the cell periphery was then calculated for each coverslip.
Quantification of FRET Biosensor Dynamics
Prior to each experiment, AKAR3 transfected AN3 CA cells plated on 25 mm
coverslips were incubated at 37°C for 30 minutes in standard extracellular solution (SES;
1.5 mM CaCl2 dihydrate, 145 mM NaCl, 5 mM KCl, 1 mM MgCl2 anhydrous, 10 mM
glucose, 10 mM Hepes, pH 7.3) containing 10 μM IBMX (3-isobutyl-1-methylxanthine;
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Sigma I-7018). Dual CFP/FRET images of the cells were acquired at 30-second intervals
using the Nikon TE300 inverted microscope and the 40x/1.3NA Oil Plan Fluor objective
lens. Filters used consisted of a 440AF21 excitation filter, a 455DRLP dichroic mirror
and two emission filters (480AF30 for CFP and 535AF26 for FRET) mounted in a filter
wheel. Excitation light intensity was adjusted using neutral density filters to minimize
photobleaching. Acquisition parameters were the same for each experiment (Fig. II-7).
Confocal Microscopy
Live-cell imaging of cells co-transfected with gravin-EYFP and PKA RII-ECFP
were obtained using a Zeiss 510 META laser scanning confocal microscope, with a Zeiss
100x Plan-Fluar oil objective lens (NA 1.45). Cells were incubated in regular SES
medium and maintained at 37°C throughout each experiment. Two color imaging was
performed to simultaneously capture EYFP and ECFP fluorescence: EYFP excitation
light was generated with a 514 nm argon laser operated at 10% power, and ECFP was
excited by a 458 nm argon laser at 80% power. Fluorescence emissions were passed
through a NFT 515 beam splitter; 475 nm ECFP longpass filter and 530 nm EYFP
longpass filter. Because control images of cells expressing gravin-EYFP or PKA RIIECFP alone were critical in demonstrating minimal signal crossover, detector gain and
amplifier offset settings were changed only slightly (EYFP channel: 825-900 gain, -0.18
to 0.01 offset; ECFP channel: 1150-1250 gain, -0.13 to -0.01 offset). Post-acquisition
adjustments to image brightness and contrast were applied equally across corresponding
images from different experimental treatments.
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Table II-1. List of reagents used in this study.
Name

Abbreviation

Source

Description

Calbiochem

Catalog
#
196419

1,2-Bis
(2-aminopheoxy)
Ethane-N,N,N’,N’tetraacetic acid
tetrakis
(acetoxymethylester)
3-Isobuty1-1methylxanthine

BAPTA-AM

IBMX

Sigma

I-7018

Adenosine 5’triphosphate
disodium salt
hydrate
Alkaline
phosphatase
conjugate
Bisindolylmaleamide

ATP

Sigma

A2383

Inhibits cAMP
hydrolysis, inhibits
phosphodiesterases
Purinergic receptor
agonist

BIM

Calbiochem

203290

PKC inhibitor

Bovine Serum
Albumin

BSA

Sigma

A-7030

CY3 2° antibody

CY3

Jackson
Immunoresearch
Sigma

715165150
D5628

Used to block nonspecific antibody
binding
Donkey anti-mouse

Sigma

F6886

Working
Conc.
10 μM

100 mM
(DMSO)

10 μM

Solid

100 mM

Secondary antibody
for Western blot

Digitonin

Forskolin

Fsk

Gravin 1°
monoclonal antibody
Gravin 1° polyclonal
antibody
I-Block™ Reagent

2B3-1.1

Ionomycin
Normal Goat Serum

Rb7753
Tropix

A1300

IM

Calbiochem

407952

NGS

Thermo
Scientific

31873

Polysciences,
Inc.
Sigma

00380

Tropix® CDP Star®

Applied
Biosystems

T2218

Tween® detergent

Sigma

P7949

Paraformaldehyde
Thapsigargin

Calcium chealator

Stock
Conc.
50 mM
(DMSO)

Tg

T9033
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Permeabilizes cell
membranes for IF
antibody labeling
cAMP elevation,
stimulates adenylyl
cyclase
Mouse antibody for
immunofluorescence
Rabbit antibody for
Western blot
Blocking buffer
used in Western blot
Calcium elevator
Used to block nonspecific antibody
labeling
Fixes cells for IF
labeling
Calcium elevator
Chemiluminescence
reagent for Western
blot
Used in some
Western blot buffers

1:100,000

2mM
(DMSO)
Solid

20 μM

1.4
mg/ml

1:200

50
mg/ml

6.2 µl/
10 ml in
1x PBS
10 μM

100 mM
(DMSO)

0.1% in
1xPBS

Ascites
(mouse)
Serum
(rabbit)
Solid

1:1,000

2 mM
(DMSO)
60
mg/ml

1 μM

Solid

3.7%

10 mM
(DMSO)

1 μM,
10 μM

1:5,000
.02%

5% or 1%

0.1%
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Mutation

Mutation
Addition

(mutCB4)
Gravin-V5/His

Lck-AKAR3

Deletion

Deletion

Deletion

Deletion

Type
Deletion

(mutCB4)
Gravin-EGFP

(ΔPB1-3+)
Gravin-EGFP

(ΔPB1-3, CB4)
Gravin-EGFP

(ΔCB4) GravinEGFP

(ΔPKA) GravinV5/His

Name
(ΔPKA) GravinEGFP

See primers

Δ125–2011

Δ125–2086

Δ2005–2079

Δ4621–4662

Nucleotides
Δ4621–4662

V673A
V677A
L682A

42-671

42-696

667-693

Δ15411554

Amino
Acids
Δ15411554

Oligonucleotide
lnker (between
HindIII and
BamHI)

Fragment swap

Site-directed
mutagenesis

SacII site insert,
then SacII digest

SacII site insert,
then SacII digest

Site-directed
mutagenesis

Fragment swap

Method
Site-directed
mutagenesis

Table II-2. Expression vectors created for this study.

5’AGCTTGCCACCATGGGCTGTGTCTGCAGCTCAAACCCTGAAAAG;
5'GATCCTTTTCAGGGTTTGAGCTGCAGACACAGCCCATGGTGGCA

5’CATCTTGGGAAGCTGCAATTTGTGTG
5’CTGAGGTATCCGCCTTTCGCTTTGGT

5'GCAAGGAGAAGT[CCGCGG]CTGATGAGGAA
5′GGTGCGTCAAAGTCGGCTACGGGGGTGC

5′CCAAAGC[CCGCGG]TGGATACCTCAGTATCT
5′GGTGCGTCAAAGTCGGCTACGGGGGTGC

5′AGGTCGTCTTCTGATGAGGAAGGGGGACCA
5′TGGTTCTTCCGGCTTTGGCTCTTCAACGCT

Primers
5′ACAGCCGTTGACCAGTTTGTACGTACAGAA
5′TTCCAAAATCCCATTTTCAGGCTCTAAATC

Figure II-1.

Optimization of transfection conditions for co-expression of AKAR3 and
non-fluorescent gravin-V5/His constructs. Plasmid DNA of gravin-V5/His
and AKAR3-CAAX were mixed at different microgram ratios prior to
transfection while maintaining a constant concentration of 1μg of DNA
per 1 ml of growth medium. After transfection, cells expressing gravin
were detected by immunofluorescence labeling with a gravin primary
antibody and CY3 secondary antibody and imaged through a CY3
fluorescence channel. Cells expressing AKAR3-CAAX were detected
using a CFP channel. Cell counts on multiple coverslips were performed
to determine the percentage of AKAR3 transfected cells which were also
transfected with gravin-V5/His. As seen in the graph, the highest
percentage was seen when the gravin:AKAR3 microgram ratio of 3:1 was
used. This was used for all subsequent experiments in which V5/His
tagged gravin constructs and AKAR3 constructs were used together.
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Figure II-2.

Schematic diagram of filter cubes used on the Nikon TE300 microscope.
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Figure II-3.

Filters and acquisition settings for Fura-2 fluorescence imaging on the
Nikon TE300 microscope.

Figure II-4.

Filters and acquisition settings for EGFP fluorescence imaging on the
Nikon TE300 microscope.
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Figure II-5.

Quantification of gravin-EGFP redistribution. This was accomplished by
measuring fluorescence intensity along a line transect across the plasma
membrane using ImageJ (A). When gravin-EGFP was localized to the cell
cortex, the fluorescence intensity along this line yielded a sharp peak in
intensity at the membrane with cytosolic intensity following the peak.
However, as gravin-EGFP underwent redistribution away from the
membrane and into the cytosol, the membrane intensity decreased while
the cytosolic intensity increased (B). The average fluorescence intensity at
the membrane and at the cytosol was determined for each time point (C)
and plotted as a ratio of membrane to cytosolic intensity over time (D).
Ratios of membrane to cytosolic intensity (Mem/Cyt) were normalized by
dividing each ratio in the time series by the average ratio value prior to
treatment.
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Figure II-6.

Quantification of gravin localization at the cell periphery. Nine images
were acquired per coverslip at these pre-defined locations on a grid that
was mounted to the stage of the Nikon TE300 microscope.

Figure II-7.

Filters and acquisition settings for FRET and CFP fluorescence imaging
on the Nikon TE300 microscope.
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Abstract
A-Kinase Anchoring Proteins (AKAPs) direct the flow of cellular information by
positioning multiprotein signaling complexes into proximity with effector proteins.
However, certain AKAPs are not stationary but can undergo spatiotemporal redistribution
in response to stimuli. Gravin, a 300kD AKAP that intersects with a diverse signaling
array, is localized to the plasma membrane but has been shown to translocate to the
cytosol following the elevation of intracellular calcium ([Ca2+]i). Despite the potential for
gravin redistribution to impact multiple signaling pathways, the dynamics of this event
remain poorly understood. In this study, quantitative microscopy of cells expressing
gravin-EGFP revealed that Ca2+ elevation caused the complete translocation of gravin
from the cell cortex to the cytosol in as little as 60 seconds of treatment with ionomycin
or thapsigargin. In addition, receptor mediated signaling was also shown to cause gravin
redistribution following ATP treatment, and this event required both [Ca2+]i elevation and
PKC activation. To understand the mechanism for Ca2+ mediated gravin dynamics,
deletion of calmodulin-binding domains revealed that a fourth putative calmodulin
binding domain called CB4 (a.a. 670-694) is critical for targeting gravin to the cell cortex
despite its location downstream of gravin’s membrane-targeting domains, which include
an N-terminal myristoylation site and three polybasic domains. Finally, confocal
microscopy of cells co-transfected with gravin-EYFP and PKA RII-ECFP revealed that
gravin redistribution mediated by ionomycin, thapsigargin, and ATP each triggered the
gravin-dependent loss of PKA localized at the cell cortex. Our results support the
hypothesis that gravin redistribution regulates cross-talk between PKA-dependent
signaling and receptor-mediated events involving Ca2+ and PKC.
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Introduction
Compartmentalization of intracellular signaling molecules is essential to signal
transduction and is achieved in part by scaffold proteins, which have the ability to shape
and direct intracellular signaling networks by organizing molecular complexes into
distinct subcellular compartments (Good et al., 2011). The ability of scaffold proteins to
control the flow of signal transduction in space and time gives them a powerful role in
regulating cellular behavior. Conceptually, scaffold proteins help provide a framework
for understanding how sophisticated signaling networks can function accurately and
efficiently among a widely diverse milieu of intracellular signaling proteins, some with
opposing effects. PKA, a critical intracellular enzyme with several hundred
phosphorylation substrates (Gao et al., 2008), relies heavily upon spatial targeting to
exert its signaling effects. This occurs largely through A-Kinase Anchoring Proteins
(AKAPs), which anchor PKA to various subcellular locations through a conserved
amphipathic helical domain and a widely varied subcellular targeting domain. AKAPs are
known to localize to a number of cellular compartments including the cytoskeleton,
plasma membrane, nucleus, Golgi, and endoplasmic reticulum, positioning multiprotein
signaling complexes into proximity with other effector proteins (reviewed in Welch et al.,
2010). Numerous reports demonstrate that the loss of PKA compartmentalization
significantly disrupts PKA signaling and leads to a many physiological dysfunctions, for
example, in memory (Nijholt et al., 2008), immune response (Schillace et al., 2009), and
cytoskeletal dynamics (Y. Wang et al., 2006).
The AKAP12 gene encodes a 300kD AKAP known as gravin in humans (Gordon
et al., 1992; Nauert et al., 1997) or SSeCKS (Lin, Tombler, Nelson, Ross, & Gelman,
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1996b) in rodents, that binds the RII subunit of PKA and is expressed in a variety of cell
types and tissues (Grove et al., 1994). Three isoforms of gravin have been described
(gravin-α, -β, -γ) which differ in subcellular localization (Streb et al., 2004). The
canonical α isoform used in this study is expressed in humans and is localized to the cell
cortex through an N-myristoylation sequence and by three polybasic domains (PB1-3)
which adhere to negatively charged phospholipids (Tao et al., 2006; X. Yan et al., 2009).
Like many AKAPs, gravin is a multivalent scaffold and interacts not only with PKA, but
also with PKC (Grove & Bruchey, 2001; Nauert et al., 1997; Piontek & Brandt, 2003),
phosphodiesterase 4D (D. Willoughby, W. Wong, J. Schaack, J. D. Scott, & D. M.
Cooper, 2006a), Ca2+/calmodulin (Tao et al., 2006), and the β2-adrenergic receptor (G.
Fan, E. Shumay, H. Wang, & C. C. Malbon, 2001; F. Lin, H. Wang, & C. C. Malbon,
2000; Shih, Lin, Scott, Wang, & Malbon, 1999a; Tao et al., 2003). Accordingly, gravin
has been implicated in a wide range of cellular functions. Gelman and colleagues have
published extensively on the role of SSeCKS as a tumor suppressor (Akakura et al., 2008;
Gelman, 2010; Gelman, Lee, Tombler, Gordon, & Lin, 1998; Gelman et al., 2000). Along
similar lines, Choi et al. (M. C. Choi, Lee, Kim, Park, et al., 2008) demonstrated in
human SNU-449 heptaocellular cancer cells that gravin is critical in cytokinesis and
interacts with actin and myosin light chain kinase during cell division. More recently,
Scott and colleagues showed that gravin recruits Polo-like kinase to the mitotic spindle to
regulate cell cycle progression (D. A. Canton et al., 2012). Malbon and colleagues
determined that gravin associates with the β2-adrenergic receptor in A293 cells and is
crucial in regulating this receptor’s desensitization and resensitization (G. Fan et al.,
2001; F. Lin, H. Wang, et al., 2000; Shih et al., 1999a; Tao et al., 2003). Willoughby et
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al. (Willoughby et al., 2006a) determined that gravin-anchored PKA and PDE4D
establish a negative feedback loop for regulating [cAMP] in the submembrane
compartment of HEK293 cells. It is clear from these examples that gravin intersects with
a broad network of signaling pathways; however the precise molecular dynamics behind
these diverse functions remain poorly understood.
Although gravin (α isoform) localizes at the plasma membrane under basal
conditions, it is known to translocate to alternative subcellular compartments in response
to stimuli. Further knowledge of this may be critical in understanding how gravin
regulates the activity of its binding partners. Redistribution of gravin from the cell
periphery to the cytosol has been demonstrated in response to PKC activation by phorbol
ester treatment (Nelson, Moissoglu, Vargas, Klotman, & Gelman, 1999; Piontek &
Brandt, 2003). Previous work in our lab demonstrated that PKC activity directs gravin to
a vesicular compartment near the nucleus, and that this translocation also causes similar
redistribution of PKA (X. Yan et al., 2009). In addition, elevation of intracellular calcium
concentration ([Ca2+]i) has been shown to cause gravin redistribution through a presumed
mechanism involving Ca2+/calmodulin (CaM) binding to gravin’s membrane-associated
polybasic domains (PB1, 2 and 3) (Tao et al., 2006). Although CaM binding to PB1-3 has
been clearly demonstrated, the notion that this interaction is alone responsible for Ca2+
mediated gravin redistribution may be incomplete in light of our previous findings which
show that the myristoylation site is sufficient to target gravin to the plasma membrane
even in the absence of PB1-3 (X. Yan et al., 2009). While it is likely that CaM binding to
PB1-3 contributes to the dissociation of gravin from the plasma membrane, the role of the
myristoylation sequence in the event is yet to be determined. In addition, it is currently
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unknown whether calcium mediated gravin redistribution also results in the redistribution
of PKA, or if these dynamics are linked to receptor-mediated signaling. Given that PKA
signaling often relies heavily on spatial compartmentalization, the findings that both
[Ca2+] elevation and PKC activation lead to gravin redistribution raise the interesting
possibility that signaling cascades involving Ca2+ and/or PKC may engage in cross-talk
with PKA-dependent signaling events through the redistribution of gravin. This would be
a novel finding particularly with regard to Ca2+/PKA crosstalk, which has been thought to
occur primarily through Ca2+ sensitive adenylyl cyclases and phosphodiesterases which
regulate cAMP concentrations. From these observations, we hypothesize that gravin
redistribution is mediated by receptors which trigger [Ca2+]i elevation and/or PKC
activation, and that these dynamics also cause the redistribution of PKA.
To test the hypothesis that calcium-mediated gravin redistribution also triggers
PKA redistribution, we used fluorescent constructs of gravin and PKA RII to determine
the effect of cytosolic calcium increase on gravin-PKA localization. Our results revealed
that both gravin and PKA are redistributed away from the cell periphery following
extracellular calcium influx, release of calcium from intracellular stores, or upon
activation of purinergic receptors by ATP. In addition, these studies demonstrate that
purinergic P2Y receptors utilize both PKC activation and [Ca2+]i increase to trigger
gravin-PKA redistribution. Although calcium-mediated gravin redistribution has been
proposed to occur through CaM binding to polybasic regions 1-3, our studies additionally
demonstrate that the deletion of these regions had no effect on gravin redistribution. A
fourth calmodulin binding domain, termed CB4, was also assessed to determine the role
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of calmodulin binding on gravin redistribution; however deletion of this region
dramatically reduced the membrane localization of gravin.
Results
Ionomycin and Thapsigargin Cause the Calcium-Dependent Redistribution of Gravin
Treatment of cells expressing gravin-EGFP with the calcium ionophore
ionomycin (1μM) resulted in the complete translocation of gravin-EGFP from the cell
cortex to the cytosol (Fig. III-1A images). Plots of the ratio of membrane to cytosolic
fluorescence over time revealed that gravin redistribution began immediately after
ionomycin treatment and was complete within 60 seconds, at which time [Ca2+]i elevation
reached its plateau (Fig. III-1B,C).
To determine if ionomycin mediated redistribution of gravin-EGFP was indeed
calcium-dependent, inhibition studies were performed in regular and Ca2+ free SES
medium by treating cells with BAPTA-AM (10 μM), a high-affinity intracellular calcium
chelator, for 30 min prior to ionomycin treatment. In regular SES medium, control
ionomycin treatments with no BAPTA-AM resulted in the complete redistribution of
gravin and an immediate, sustained increase in [Ca2+]i (Fig. III-2A,B). In Ca2+ free SES,
ionomycin caused both the increase of [Ca2+]i and the redistribution of gravin, although
the magnitude and duration of calcium increase were substantially reduced (Fig. III2E,F). This finding is consistent with other studies which have demonstrated that
ionomycin targets the release of calcium from intracellular stores in addition to triggering
extracellular calcium influx (Morgan & Jacob, 1994; Yoshida & Plant, 1992). Ionomycin
mediated gravin redistribution and cytosolic calcium increase were both fully prevented
in Ca2+ free SES when BAPTA-AM was present (Fig. III-2G,H), confirming that
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ionomycin mediated gravin redistribution is calcium dependent. Surprisingly, pretreatment of cells with BAPTA-AM in regular SES also showed ionomycin-mediated
gravin redistribution and a sustained [Ca2+]i increase; however there was a 60 second
delay in gravin redistribution and [Ca2+]i increase (Fig. III-2C,D). Even at BAPTA-AM
concentrations as high as 500 μM, ionomycin caused gravin redistribution in regular SES
(not shown) and suggests that the intracellular BAPTA-AM concentration required to
prevent [Ca2+] elevation in these cells could not be achieved. Nonetheless, our finding
that BAPTA-AM prevented gravin redistribution in Ca2+ free SES demonstrated that
ionomycin-mediated gravin redistribution was calcium-dependent.
To examine the effect of [Ca2+]i increase through the release of Ca2+ from
intracellular stores on gravin distribution, cells expressing gravin-EGFP were treated with
thapsigargin, an agent which rapidly elevates cytosolic calcium by inhibiting SERCAmediated Ca2+ reuptake into the endoplasmic reticulum (Lytton, Westlin, & Hanley,
1991). Upon treatment with thapsigargin (0.4 μM), gravin-EGFP underwent
redistribution from the cell periphery to the cytosol in both the presence and absence of
extracellular Ca2+. Thapsigargin mediated calcium increase peaked within 60 seconds and
then gradually decreased to basal levels over the course of several minutes (Fig. III-3AB,E-F). Pre-treatment of cells with BAPTA-AM (10 μM) 30 minutes prior to
thapsigargin treatment prevented gravin redistribution and cytosolic calcium increase in
both regular and Ca2+ free SES (Fig. III-3C-D,G-H). These results confirm that
thapsigargin elicited gravin redistribution in a calcium-dependent manner, raising the
possibility that receptor-mediated signaling events which target the release intracellular
Ca2+ stores into the cytosol would also cause the redistribution of gravin.
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Role of Putative Calmodulin Binding Domains in Ca2+-Mediated Gravin Redistribution
Currently, the mechanism underlying redistribution of gravin in response to
elevated [Ca2+]i is poorly understood. However, a study by Tao et al. (Tao et al., 2006)
proposed that calcium mediated gravin redistribution occurs as a result of
Ca2+/calmodulin binding to three polybasic domains located in the N-terminal half of
gravin (PB1-3) and inhibiting their association with the plasma membrane (Tao et al.,
2006), Based on this, we predicted that deletion of PB1-3 would alter the rate of gravin
redistribution in response to ionomycin treatment. However, fluorescence microscopy
revealed that a gravin-EGFP construct lacking the three polybasic domains (ΔPB1-3)
localized to the cell cortex prior to treatment and underwent redistribution from the cell
cortex to the cytosol at an identical rate to the wild type gravin construct after ionomycin
treatment (Fig. III-4A). This suggests that the polybasic domains PB1-3 are not required
for calcium-mediated redistribution of gravin.
The study by Tao et al. (Tao et al., 2006) also revealed the location of a possible
fourth calmodulin binding domain on gravin between amino acids 670-694 which, unlike
polybasic domains 1-3, did not bind to phospholipid vesicles. This fourth putative
calmodulin binding domain (CB4) conforms to a 1-5-10 consensus sequence for
Ca2+/calmodulin binding (Rhoads & Friedberg, 1997) and corresponds exactly to the
SSeCKS-3 domain, which was shown to bind calmodulin in SSeCKS, the murine
orthologue of gravin (Lin & Gelman, 2002). To further understand the role of all four
calmodulin binding domains of gravin in Ca2+ mediated redistribution, additional mutant
gravin constructs were generated with the intent of comparing their rates of redistribution
to that of the full length (WT) gravin. A gravin-EGFP construct lacking the polybasic
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domains and everything up to but not including the CB4 domain (ΔPB1-3+) localized to
the cell cortex prior to treatment, but in response to ionomycin (1 μM) underwent
translocation of away from the cell cortex at a significantly delayed rate compared to WT
gravin (Mann-Whitney Rank Sum Test, horizontal bar denotes time points at which p <
0.05) (Fig. III-4B). Surprisingly, a gravin-EGFP construct lacking the three polybasic
domains and the fourth putative calmodulin binding domain (ΔPB1-3, CB4) did not
localize at the cell cortex in a manner which was sufficient to measure its rate of
redistribution. As illustrated in Fig. III-4C, 75.7% (± 14.8%, 231 cells) of cells
transfected with full-length (WT) gravin-EGFP, displayed cortically localized
fluorescence, while only 17.8% (± 11.4%, 215 cells) of cells expressing (ΔPB1-3,CB4)
gravin-EGFP displayed any appreciable cortical fluorescence. Normal membrane
localization was observed in (ΔPB1-3+) gravin-EGFP (81.7% ±10.2%, 125 cells)
compared to WT gravin, but a gravin-EGFP construct lacking only the CB4 domain
(ΔCB4) localized to the cell cortex in significantly fewer transfected cells (19.7% ±
6.2%, 90 cells) (ANOVA followed by Holm-Sidok post-hoc, significant differences from
WT gravin denoted by asterisks, p < 0.05).
The expression of the mutant gravin–EGFP vectors was confirmed in AN3 CA
cells by Western blotting using an anti-gravin antibody. As seen in Fig. III-4D, the lanes
loaded with lysates from different gravin–EGFP transfectants showed gravin expression
at the positions that matched the size of the desired gravin–EGFP mutants. No gravin
expression was detected in control untransfected cells. These findings demonstrate that
the presence of the CB4 domain is critical in targeting gravin to the cell cortex, and that
this domain seems to regulate the membrane-binding activity of upstream domains (myr,
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PB1-3) which have been well-characterized as necessary for membrane localization.
These results also suggest that activity at this domain may in fact regulate the
redistribution of gravin. While this activity is likely to involve Ca2+/calmodulin binding,
future studies will be required to understand the precise function of Ca2+/calmodulin at
this region.
ATP Mediated Gravin Redistribution Involves Both Ca2+ and PKC
Since gravin was demonstrated to undergo redistribution from the cell membrane
to the cytosol after ionomycin and thapsigargin treatment, we sought to determine if
gravin redistribution would occur through receptor signaling linked to [Ca2+]i elevation.
ATP is well known to induce an increase in [Ca2+]i through both ionotropic (P2X) and
metabotropic (P2Y) purinergic receptors. While P2X receptors trigger the influx of
extracellular calcium, P2Y receptors stimulate cytosolic calcium increases primarily
through their association with Gq/11, which activates PLCβ to stimulate both PKC
activation and InsP3 mediated release of calcium from intracellular stores (Erb, Liao,
Seye, & Weisman, 2006; Weisman et al., 2006). Treatment of HEC-1A cells with 10 mM
ATP resulted in a change in gravin-EGFP distribution from the cell cortex to the cytosol.
This change was also accompanied by an immediate increase in [Ca2+]i followed by a
subsequent decrease back to basal levels (Fig. III-5A,B). ATP-mediated gravin
redistribution and [Ca2+]i increase also occurred in Ca2+ free SES (Fig. III-5C,D), a result
consistent with P2Y receptor activation.
To determine the mechanism of ATP-mediated gravin redistribution in HEC-1A
cells, inhibition studies were performed using bisindolylmaleamide (BIM, 1 μM), a PKC
inhibitor, and/or BAPTA-AM (50 μM). Treatment with 10mM ATP caused complete
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redistribution of gravin from the cell membrane to the cytosol, compared to cells with no
ATP added (Fig. III-6A-D). ATP treatment in the presence of either BIM or BAPTA-AM
(Fig III-6E-H) caused partial redistribution of gravin, while ATP treatment in the
presence of both inhibitors showed no gravin redistribution (Fig. III-6I-J). Measurement
of the ratio of membrane to cytosolic fluorescence at each time point revealed that BIM
and BAPTA-AM significantly attenuated ATP-mediated gravin redistribution (Fig. III6K,L). However, treatment with both BAPTA-AM and BIM together was necessary to
completely prevent gravin redistribution in cells treated with ATP (Fig. III-6M),
suggesting that both Ca2+ and PKC are required for ATP-mediated gravin dynamics.
Statistical analyses were performed at each time point using a Mann-Whitney Rank Sum
Test (horizontal bars denote time points at which p < 0.05). Analysis of the maximum
change in membrane to cytosolic ratio for each of the treatments further revealed three
statistically significant subsets: ATP in the presence of no inhibitors showed the greatest
change in gravin distribution; ATP in the presence of either BIM or BAPTA-AM showed
a significantly reduced change in gravin distribution; and ATP in the presence of both
BIM and BAPTA-AM showed no difference in gravin distribution from untreated cells
(ANOVA followed by Holm-Sidok post-hoc, significantly different subsets denoted by
asterisks, p < 0.05) (Fig. III-6N).
Loss of Cortical PKA Compartmentalization Following Gravin Redistribution.
Since a major function of AKAPs is to direct PKA to specific subcellular
compartments, we sought to examine whether Ca2+-mediated or purinergic receptormediated gravin redistribution also causes the redistribution of PKA. We used confocal
microscopy to simultaneously visualize the subcellular distribution of gravin-EYFP and
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PKA RII-ECFP before and after treatment with ionomycin, thapsigargin, or ATP. As
seen in Fig. III-7, expression of PKA RII-ECFP was distributed throughout the cytosol in
cells transfected with PKA RII-ECFP alone or when co-transfected with a gravin
construct lacking the PKA-binding domain, (ΔPKA) gravin-EYFP, but PKA RII-ECFP
was concentrated at the cell periphery in cells co-expressing WT gravin-EYFP.
Treatment of cells with ionomycin, thapsigargin, or ATP resulted in in the loss of PKA
RII-ECFP localization at the cell cortex, concurrent with the redistribution of gravinEYFP (Fig. III-7A-F’). These studies demonstrate that signaling events that trigger
translocation of gravin also alter the subcellular distribution of PKA.
Discussion
The aim of the current study was to characterize the redistribution of gravin
following an increase in [Ca2+]i and determine its effect on subcellular PKA localization.
This study demonstrated that gravin undergoes subcellular redistribution following
treatment with ionomycin or thapsigargin, both from extracellular Ca2+ influx and from
intracellular store release. Calcium mediated redistribution of gravin does not require the
presence of polybasic domains 1-3, three regions rich in basic amino acids which bind
Ca2+/calmodulin and are involved in targeting gravin to the plasma membrane.
Interestingly, deletion of a fourth calmodulin binding domain (amino acids 670-694)
which is reported to not associate with phospholipid vesicles (Tao et al., 2006) resulted in
a dramatic decrease in the localization of gravin at the cell cortex. This study also
demonstrated that purinergic receptor mediated elevation of [Ca2+]i and activation of
PKC can also induce gravin redistribution. Finally, ionomycin, thapsigargin, and ATP
mediated gravin redistribution also triggered the loss of PKA localization at the cell
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cortex. Our results support the hypothesis that receptor mediated signaling events
involving calcium and/or PKC can influence cAMP-dependent signaling through the
spatial regulation of gravin.
Calcium mediated redistribution of gravin was first reported by Tao et al. (Tao et
al., 2006) to occur in response to A23187, a calcium ionophore. The current study adds to
this finding in several important ways. First, our approach revealed that gravin
redistribution occurs immediately following treatment with the calcium elevating agents
ionomycin, thapsigargin, or ATP, and that these agents caused the complete redistribution
of gravin from the cell periphery to the cytosol in as little as 60 seconds. Second, our
findings with ionomycin and thapsigargin demonstrated that gravin redistribution can be
mediated by both influx of extracellular calcium and the release of calcium from
intracellular stores. Third, our approach demonstrated that both sustained and transient
increases in cytosolic calcium following ionomycin or thapsigargin treatment were
sufficient to mediate the complete redistribution of gravin. Finally, the current study
demonstrated that Ca2+ signaling is involved in receptor-mediated gravin redistribution
following ATP treatment. In these experiments ATP-generated Ca2+ transients were
sufficient to cause partial gravin redistribution, in contrast to experiments involving
ionomycin and thapsigargin, which caused complete gravin redistribution. This apparent
contrast suggests that while Ca2+ alone may be sufficient for complete gravin
redistribution under certain conditions, the mechanisms involved in receptor-mediated
gravin redistribution may be more complex. Indeed, our findings demonstrate that ATPmediated gravin redistribution also acted through PKC activity in addition to [Ca2+]i
elevation. Previous reports have shown that PKC activation causes gravin redistribution
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and complements our finding that PKC is involved in ATP-mediated gravin redistribution
(Nelson, Moissoglu, Vargas, et al., 1999; Piontek & Brandt, 2003; X. Yan et al., 2009).
In sum, the results of the current study further our understanding of the real-time
dynamics behind Ca2+ mediated gravin redistribution, and provide additional insight into
its biological context and molecular mechanism.
Although the mechanism behind calcium mediated redistribution of gravin has yet
to be fully elucidated, previous work indicates the involvement of Ca2+/calmodulin
(CaM). Tao et al. (Tao et al., 2006) reported compelling evidence that CaM interacts with
the membrane-binding polybasic domains (PB1-3) of gravin to cause the dissociation of
these domains from phospholipid vesicles, but this work used gravin constructs lacking
the N-terminal myristoylation sequence. More recently, work in our lab demonstrated
that the myristoylation sequence is sufficient to target gravin to the plasma membrane,
even in the absence of the polybasic domains (13). We therefore postulated that a
myristoylated gravin construct lacking the polybasic domains would not undergo
redistribution in response to elevated [Ca2+]. Surprisingly, such a construct underwent
redistribution from the plasma membrane to the cytosol at the same rate as full-length
gravin. This finding indicates that CaM binding to the polybasic domains does not fully
explain the mechanism for Ca2+ mediated redistribution of myristoylated gravin. Indeed,
the membrane-binding activity of the myristoylation site must also be altered by [Ca2+]i
elevation. Our results suggest that CaM interaction with an additional calmodulin binding
domain, termed CB4, may regulate the membrane targeting of gravin. This CB4 domain
conforms to the 1-5-10 consensus sequence for CaM binding
(669KRKVDTSVSWEALICV) and is identical to the SSeCKS-3 domain found in the rat
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orthologue of gravin, reported by Lin and Gelman to bind CaM in vitro (Lin & Gelman,
2002). Deletion of the four known gravin calmodulin binding domains (ΔPB1-3, CB4)
resulted in a dramatic loss of membrane localization of gravin, while reconstitution of
only the CB4 domain fully restored membrane localization to that of full-length gravin.
Moreover, deletion of CB4 alone caused a similar loss of membrane localization to that
of (ΔPB1-3,CB4) gravin-EGFP. These results are the first to demonstrate that the CB4
domain is critical in the subcellular localization of gravin. Although the precise effect of
CB4 deletion is unclear, one possibility is that CB4 deletion mimics CaM binding to
gravin. Nonetheless, our results support the notion that calcium-mediated gravin
redistribution operates through a mechanism which involves the interaction of CaM with
gravin.
Our findings that gravin redistribution occurs from both intracellular calcium
influx and from the release of calcium from intracellular stores suggest that gravin
redistribution occurs across a variety of physiological contexts. These modes of calcium
signaling are central to cellular homeostasis and exist not only in G protein coupled
receptor (GPCR) systems, but also in the form of plasma membrane channels such as
ionotropic receptors, cyclic-nucleotide gated channels, L-type channels, and membrane
components of store operated calcium entry (SOCE). Thus, signaling through any one of
a number of pathways that induce an increase in cytosolic [Ca2+] may result in the
redistribution of gravin and affect the signaling dynamics of molecules associated with
gravin. Our finding that ATP triggered redistribution of gravin through a pathway that
involved both [Ca2+]i increase and PKC activation supports this notion and indicates that
GPCR signaling through the canonical Gq/11 pathway may be a major pathway for gravin
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redistribution. Given the widespread occurrence of signaling pathways involving these
modes of signaling, gravin redistribution is likely to be a widespread response to
signaling events and could serve as an important mediator for cross-talk over the
signaling dynamics of molecules bound to the gravin scaffold. Since gravin interacts with
a diverse array of signaling molecules including PKA, PKC, PDE4, β2-adrenergic
receptor (β2AR), cyclin D and others (Gelman, 2002; Gelman & Gao, 2006; Tao et al.,
2003; Willoughby et al., 2006a), subcellular translocation of this AKAP would likely
affect signaling events involving these binding partners. PKA, for instance, is known to
require spatial compartmentalization by AKAPs (Skroblin, Grossmann, Schafer,
Rosenthal, & Klussmann, 2010). Thus, loss of cortically-localized gravin/PKA would
likely affect PKA signaling by reducing activity at the plasma membrane or directing
PKA signaling to another subcellular compartment. β2AR signaling is known to be
regulated by gravin expression and redistribution in a variety of contexts (G. Fan et al.,
2001; F. Lin, H. Wang, et al., 2000; Shih et al., 1999a; Tao et al., 2006; Tao et al., 2003)
and thus receptor mediated events leading to gravin redistribution would most certainly
impact a wide range of β2AR dependent physiological activities known to be linked to
gravin. Finally, reports that PDE4 binds to gravin and that this complex regulates cortical
cAMP levels suggest that receptor mediated relocalization of gravin could impact cAMP
dependent signaling broadly by altering dynamic control of [cAMP].
Conclusions
We report that gravin undergoes rapid redistribution from the cell periphery to the
cytosol following treatment with the calcium-elevating agents ionomycin, thapsigargin,
or ATP, and that this redistribution is accompanied by a change in subcellular PKA
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localization. The effect of ionomycin and thapsigargin on gravin distribution was calcium
dependent, whereas ATP’s effect on gravin distribution involved both calcium and PKC.
Surprisingly, calcium mediated redistribution of myristoylated gravin did not require
polybasic regions 1-3, but deletion of a 1-5-10 consensus sequence for calmodulin
binding downstream of the polybasic regions seems to regulate the targeting of gravin to
the cell cortex. Our data supports the hypothesis that receptor mediated signaling events
involving calcium and/or PKC can alter cAMP-dependent signaling through the spatial
regulation of gravin and anchored PKA. This finding suggests that gravin facilitates a
novel cross-talk mechanism in which cAMP-dependent signaling pathways are altered by
calcium and PKC, and lays the groundwork for future studies of gravin spatiotemporal
dynamics in regulating cAMP-dependent signaling events.
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Figure III-1.

Ionomycin treatment induces gravin redistribution. (A) Fluorescent
micrographs illustrating that gravin-EGFP undergoes redistribution
immediately following the addition of 1 µM ionomycin. (B) Plot of
membrane:cytosol fluorescence intensity ratio over time illustrating the
time course of gravin redistribution. (C) Corresponding plot of the Fura2
fluorescence ratio illustrating the rapid increase in [Ca2+]i upon ionomycin
treatment. Note that gravin translocation is complete at t = 60 seconds,
which corresponds to the time at which maximal cytosolic calcium
increase is observed.
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Figure III-2.

Representative fluorescent images of gravin-EGFP and corresponding
plots of Fura2 fluorescence ratios illustrate that ionomycin-mediated
gravin distribution is calcium dependent. Note that ionomycin treatment in
both the presence and absence of extracellular calcium resulted in
elevation of intracellular calcium and redistribution of gravin. Ionomycin
treatment in the presence of BAPTA-AM (10 μM) and extracellular
calcium also resulted in a sustained increase in cytosolic calcium and
gravin redistribution. However, when BAPTA-AM was present in Ca2+
free medium, ionomycin-mediated gravin redistribution was fully
prevented. Scale bar = 10 μM.
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Figure III-3.

Representative fluorescent images of EGFP-gravin and corresponding
plots of Fura2 fluorescence ratios illustrating that thapsigargin mediated
gravin redistribution is calcium dependent. Note that thapsigargin
treatment in the presence and absence of extracellular calcium caused
redistribution of gravin concurrent with a transient increase in cytosolic
calcium. Addition of BAPTA-AM (10 μM) prior to thapsigargin treatment
fully prevented gravin redistribution in either the presence or absence of
extracellular Ca2+. Scale bar = 10 μM.
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Figure III-4.

Role of four calmodulin binding domains (PB1-3, CB4) in gravin
redistribution and subcellular localization. (A, B) Comparison of the rate
of redistribution from cell membrane to cytosol for either WT gravinEGFP and (ΔPB1-3) gravin-EGFP (A) or WT gravin-EGFP and (ΔPB13+) gravin-EGFP (B) after ionomycin treatment. The deleted regions are
illustrated below the graphs. No difference was observed between WT
gravin and (ΔPB1-3) gravin, but the rate of (ΔPB1-3+) gravin
translocation from membrane to cytosol was significantly reduced
compared to WT gravin. (Comparison at each time point revealed
significant differences between constructs as indicated by the horizontal
bar; Mann-Whitney Rank Sum Test, p < 0.05). (C) Graph illustrating the
effect of deleting the CB4 region on localization of gravin at the cell
periphery in transfected cells. Note that localization of the (ΔPB1-3, CB4)
mutant at the cell cortex was significantly reduced compared to WT
gravin. Reconstitution of the CB4 domain (ΔPB1-3+) restored membrane
localization, while deletion of the CB4 domain (ΔCB4) alone resulted in a
decrease in membrane localization similar to that of ΔPB1-3,CB4.
Astericks indicate significant differences from WT gravin-EGFP (one-way
ANOVA followed by a Holm-Sidak post-hoc test; p < 0.05). (D) A
Western blot demonstrating the expression of full-length gravin–EGFP
and its deletion mutants in AN3CA cells. Sixty micrograms total protein
was loaded in all lanes. The number of amino acids comprising each
construct is marked at the top of the blot.
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Figure III-5.

Fluorescence micrographs illustrating the effect of ATP treatment on
gravin redistribution and changes in intracellular calcium in the presence
and absence of extracellular calcium. Gravin redistribution was observed
following ATP treatment (10 mM) in both regular SES and Ca2+ free SES.
Moreover, cytosolic [Ca2+] increased to the same extent (an approximately
1.7 fold increase) in cells treated with ATP in regular and Ca2+ free SES.
Scale bar = 10 μM.
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Figure III-6.

Regulation of gravin redistribution by ATP treatment. (A-J) Fluorescence
micrographs illustrating the effect of ATP treatment (10 mM) on gravin
distribution in the presence of bisindolylmaleimide (BIM), BAPTA-AM,
or BIM and BAPTA-AM together. ATP treatment induced complete
redistribution of gravin (C,D) compared to untreated cells (A,B). Gravin
redistribution was partially attenuated when ATP was administered in the
presence of 2 μM bisindolylmaleimide (BIM) or 50 μM BAPTA-AM
(G,H). However, gravin redistribution was fully prevented when ATP was
administered in the presence of both BIM and BAPTA-AM (I,J). (K-M)
Quantitative analysis of gravin-EGFP dynamics in response to ATP in the
presence of BIM and BAPTA-AM. BIM (K) or BAPTA-AM (L) caused a
significant attenuation in the redistribution of gravin-EGFP. However,
ATP treatment in the presence of both BIM and BAPTA-AM completely
inhibited redistribution of gravin-EGFP (M). (N) Histogram illustrating
the extent to which gravin distribution changed under the different
treatment conditions. The height of the bars corresponds to the difference
between the membrane/cytosol ratio at t=0 and the minimum
membrane/cytosol ratio reached during each run. One-way ANOVA
followed by Holm-Sidak post hoc tests revealed three significantly distinct
responses to the treatments, which are denoted by asterisks (p < 0.05).
Scale bar = 10 μM.
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Figure III-7.

Confocal micrographs of HEC1A cells transfected with gravin-EYFP and
PKA RII-ECFP. PKA co-distributes with gravin at the cell cortex in cells
expressing both PKA and full-length gravin (A,A’; C,C’, E,E’), However,
redistribution of gravin following treatment with ionomycin (B, 1 μM),
thapsigargin (D, 0.4 μM), or ATP (F, 10mM) triggers the loss of PKA
localization at the cell periphery (B’, D’, F’) in concert with redistribution
of gravin. PKA RII-ECFP did not localize at the cell cortex nor change
distribution after ionomycin treatment in cells co-expressing PKA RIIECFP and a gravin–EYFP construct lacking the PKA RII binding domain
(Δ-PKA gravin; G,G’; H,H’), although the gravin construct underwent
redistribution to the cytosol. Controls transfected with either gravin-EYFP
or PKA RII-ECFP alone confirmed that the observed codistribution of
gravin and PKA was not due to cross-over of the EYFP signal into the
ECFP channel, or vice versa. Scale bar = 10 μM.
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Abstract
Scaffold proteins play a critical role in cellular homeostasis by positioning
signaling molecules in proximity to downstream effectors. However, some scaffold
proteins do not assemble static enzyme complexes, but form dynamic signalosomes that
traffic to different subcellular compartments in response to stimuli. Gravin (AKAP12), a
multivalent scaffold linked to a variety of cellular functions, anchors PKA and other
enzymes to the plasma membrane but is redistributed to the cytosol upon elevation of
[Ca2+]i . We postulate that gravin redistribution represents a novel mechanism for
crosstalk between Ca2+-dependent and cAMP-dependent signaling pathways. To assess
this, we measured the impact of gravin-V5/His expression on compartmentalized PKA
activity using the PKA FRET biosensor AKAR3. Expression of gravin-V5/His in AN3
CA cells, which lack endogenous gravin, caused an increase in forskolin-stimulated PKA
activity in AKAR3 constructs targeted to the plasma membrane compared to control cells
lacking gravin or expressing a gravin construct lacking the PKA-binding domain.
Expression of a gravin mutant with reduced membrane localization also showed no
increase in membrane PKA activity compared to control cells lacking gravin. In addition,
gravin-V5/His caused a decrease in forskolin-stimulated PKA activity in cytosolic
AKAR3 constructs compared to control cells lacking gravin, and this effect also required
PKA interaction and membrane localization. Pretreatment with thapsigargin, a calcium
elevating agent, stimulated gravin redistribution away from the membrane and prevented
gravin’s impact on membrane PKA activity. These results reveal that gravin shapes the
subcellular profile of PKA activity and support the hypothesis that gravin mediates
crosstalk between Ca2+ and cAMP-dependent signaling pathways. Based on these results,
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AKAP localization dynamics may represent an important paradigm for the regulation of
cellular signaling networks.
Introduction
Intracellular signal transduction requires precise physical interactions between
specific signaling proteins within a receptor-directed cascade. It is now clear that many of
these protein-protein interactions are facilitated by scaffold proteins and not by random
diffusion (Good et al., 2011). A-Kinase Anchoring Proteins (AKAPs) play an integral
role in this by compartmentalizing cAMP-dependent protein kinase (PKA) and other
enzymes to specific subcellular locations. AKAPs possess a conserved amphipathic
helical domain that binds the regulatory subunit of cyclic AMP-dependent kinase (PKA)
and a subcellular targeting domain that serves to anchor PKA and often additional
kinases, phosphatases, and other regulatory enzymes to diverse subcellular compartments
(reviewed in Wong & Scott, 2004). Interestingly, some AKAPs do not merely serve as
static “anchors”, but can traffic to alternative subcellular compartments in response to
stimuli (Eide et al., 1998; H. Li, Adamik, Pacheco-Rodriguez, Moss, & Vaughan, 2003;
Rawe, Payne, Navara, & Schatten, 2004; K. E. Smith, Gibson, & Dell'Acqua, 2006).
Gravin (AKAP12) is a 300 kD AKAP with dramatic spatial targeting dynamics.
Gravin binds to PKA and a host of other signaling enzymes and associates with the
plasma membrane through an N-myristoylation site and three polybasic domains (PB1-3)
which are presumed to adhere electrostatically to acidic phospholipids. In response to
either PKC activation or intracellular calcium ([Ca2+]i) elevation, gravin is redistributed
away from the membrane, removing gravin bound PKA from the cell periphery. Yan et al
(X. Yan et al., 2009) showed that PKC activation triggers the redistribution of
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gravin/PKA to a juxtanuclear vesicular compartment. In addition, Tao et al. (Tao et al.,
2006) were the first to show that elevation of intracellular [Ca2+] triggers the
redistribution of gravin to the cytosol through a mechanism thought to involve
Ca2+/calmodulin binding to PB1-3. A recent study from our laboratory further revealed
that calcium mediated gravin redistribution triggers relocalization of PKA away from the
membrane and that a fourth putative calmodulin binding domain called CB4 may be
critical in this event. In addition, this study found that receptor-mediated signaling
triggers gravin/PKA redistribution to the cytosol through a mechanism involving both
calcium and PKC (Schott & Grove, 2013). These findings raise the interesting possibility
that gravin facilitates a crosstalk mechanism in which Ca2+/PKC-dependent inputs can
modulate cAMP-dependent outputs through the redistribution of gravin. However,
gravin’s impact on subcellular PKA activity under both basal conditions and upon
Ca2+/PKC-mediated redistribution is currently unknown. This could have important
implications for gravin’s role in many health-and disease-related contexts that utilize
crosstalk between Ca2+/PKC-dependent and cAMP-dependent signaling, such as cellular
migration (Akakura & Gelman, 2012; Gelman et al., 2000; Liu, Guan, Hu, Gu, & Lu,
2011), cancer (reviewed in Gelman, 2012), learning and memory (Havekes et al., 2012),
cardiac function (Guillory et al., 2013), and vascular biology (Grove & Bruchey, 2001;
Weissmuller et al., 2014).
In the current study, we investigate the role of gravin in shaping subcellular PKA
activity and in mediating crosstalk between Ca2+ and cAMP-dependent signaling
pathways. Gravin’s role in targeting PKA to the plasma membrane suggests that gravin
potentiates PKA signaling at the plasma membrane. This suggestion in turn implies that
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Ca2+ elevation may suppress plasma membrane PKA signaling by triggering the
redistribution of gravin/PKA into the cytosol. We hypothesize that through this
mechanism, gravin mediates cross-talk between calcium and cAMP-dependent signaling
pathways. We tested this hypothesis in AN3 CA cells, a cell line that lacks endogenous
gravin, by using the FRET-based PKA biosensor AKAR3 that has been optimized to
measure PKA activity within targeted subcellular compartments (Allen & Zhang, 2006).
Using AKAR3 constructs targeted to the plasma membrane and to the cytosol, we
measured the impact of exogenous gravin-V5/His expression on compartmentalized PKA
activity at the plasma membrane and in the cytosol. In addition, we tested the impact of
calcium-mediated gravin redistribution on plasma membrane PKA activity.
Results
Forskolin Treatment Stimulates AKAR3 Dynamics
Fluorescent micrographs in Figure IV-1 illustrate the subcellular distributions of
AKAR3 constructs used in this study. AKAR3-NES contains a nuclear export signal
which confines it to the cytosol, while AKAR3-CAAX and Lck-AKAR3 are localized to
the plasma membrane. After background subtraction, FRET and CFP intensity values
over time were measured for each cell within regions of interest using ImageJ. FRET
intensity values were then corrected for CFP crossover (44% based on images of cells
expressing CFP only), and ratios of FRET/CFP intensities were plotted over time for each
cell measured. Upon treatment with forskolin, fluorescence intensity in the CFP channel
decreased while FRET intensity increased (Fig. IV-1A), causing an increase in the ratio
of FRET/CFP emissions which peaked close to 60 seconds (Fig. IV-1B). FRET/CFP
ratios were normalized by dividing each ratio in the time series by the mean of ratio
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values prior to treatment. To calculate the fold increase in FRET/CFP as a result of
forskolin treatment, the max ratio value for each cell, Rmax, was divided by the mean ratio
value prior to treatment, R0 (Fig. IV-1B-C).
Role of Gravin in Shaping Subcellular PKA Activity
To determine the effect of gravin-V5/His expression on subcellular PKA activity,
three different AKAR3 constructs were used which were localized to the plasma
membrane (AKAR3-CAAX and Lck-AKAR3) and in the cytosol (AKAR3-NES).
AKAR3-CAAX contains a motif reported to target non-raft plasma membrane
microdomains, whereas Lck-AKAR3 contains a motif reported to target membrane rafts
(Agarwal et al., 2014; Allen & Zhang, 2006; Depry, Allen, & Zhang, 2011; Gao et al.,
2011; Melkonian, Ostermeyer, Chen, Roth, & Brown, 1999; Zacharias, Violin, Newton,
& Tsien, 2002). AKAR3-NES contains a nuclear export signal which restricts this
biosensor to the cytosol (Allen & Zhang, 2006). The AN3 CA cells used in this study do
not express gravin endogenously (Schott & Grove, 2013; X. Yan et al., 2009). Prior to
microscopy, cells were equilibrated for 30 minutes in standard extracellular solution
(SES) containing the phosphodiesterase inhibitor IBMX (10 μM) to prevent cAMP
degradation. To stimulate cAMP elevation and subsequent PKA activity, we treated cells
with the adenylyl cyclase activator forskolin (10 μM) and measured changes in AKAR3
fluorescence in the presence and absence of gravin-V5/His. Upon treatment with
forskolin, we observed a sustained increase in the ratio of AKAR3 FRET/CFP
fluorescence which reached its peak value by 60 seconds. As seen in Fig. IV-2A-B,
gravin-V5/His expression significantly elevated the response of AKAR3-CAAX from
1.112 to 1.205, an increase of 45%. Gravin-V5/His expression also elevated the response
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of Lck-AKAR3 from 1.045 to 1.072, an increase of 37% (Fig. IV-2C-D). In the cytosol,
gravin-V5/His expression suppressed the response of AKAR3-NES from 1.223 to 1.178,
a decrease of 26% (Fig. IV-2E-F). From these results, we conclude that gravin expression
potentiates PKA activity in the plasma membrane in a manner which may be slightly
greater in non-raft membrane domains vs membrane rafts, but reduces PKA activity in
the cytoplasm. It is likely that gravin expression accomplishes this by anchoring PKA to
the plasma membrane and sequestering PKA away from the cytosol.
Gravin-PKA Interaction is Required for Gravin-Mediated
Shaping of Subcellular PKA Activity
.
We next sought to examine the role of gravin-PKA interaction in gravin-mediated
shaping of subcellular PKA activity using a gravin construct lacking its PKA-binding
domain. First, we quantified the subcellular localization of PKA RII at the cell periphery
in AN3 CA cells co-expressing either full-length (WT) gravin-V5/His or a (ΔPKA)
gravin-V5/His mutant which lacks the PKA binding domain. Immunofluorescence
labeling of gravin in these cells revealed that roughly 95% of cells transfected with PKA
RII-ECFP also expressed gravin-V5/His constructs, and cells expressing PKA RII-ECFP
only had no gravin (Fig. IV-3A). As seen in Fig. IV-3B, roughly 40% of cells coexpressing WT gravin-V5/His and PKA RII-ECFP showed ECFP localization along the
cell periphery. In contrast, no ECFP localization at the cell periphery was seen in cells
co-expressing (ΔPKA) gravin-V5/His and PKA RII-ECFP or in cells expressing PKA
RII-ECFP only. These results show that gravin targets PKA RII to the cell periphery, and
that the (ΔPKA) gravin-V5/His mutant has no impact on subcellular PKA localization at
the cell periphery.
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To determine if the gravin-mediated changes in subcellular PKA activity were
dependent on gravin-PKA interaction, we co-transfected AN3 CA cells with the AKAR3
constructs and either WT gravin-V5/His or a (ΔPKA) gravin-V5/His. In figure IV-4,
confocal micrographs of transfected AN3 CA cells labeled with a gravin antibody and
CY3 secondary antibody show that both full-length (WT) gravin-V5/His and (ΔPKA)
gravin-V5/His were localized to the plasma membrane. In cells expressing plasma
membrane AKAR3-CAAX, gravin-V5/His expression potentiated forskolin-stimulated
PKA activity in comparison to control cells with no gravin, but this potentiation was not
observed in cells expressing (ΔPKA) gravin-V5/His. Similarly, in cells expressing
cytosolic AKAR3-NES, gravin-V5/His expression reduced forskolin-stimulated PKA
activity compared to control cells with no gravin, but this reduction was not observed in
cells expressing (ΔPKA) gravin-V5/His. These results confirm that gravin-PKA
interaction is required for gravin-mediated potentiation of plasma membrane PKA
activity and reduction of forskolin-stimulated PKA activity in the cytosol.
Mutation of Gravin’s CB4 Domain Reduces Membrane Localization
and Gravin-Mediated Changes in Subcellular PKA Activity.
Gravin localization at the plasma membrane is aided in part by an Nmyristoylation sequence and three N-terminal polybasic domains, PB1-3 (X. Yan et al.,
2009). Tao et al. (2006) proposed that Ca2+/calmodulin (CaM) binding to PB1-3 is
responsible for calcium mediated relocalization of gravin into the cytosol (Tao et al.,
2006). However, more recently we reported that deletion of PB1-3 had no effect on the
ability of calcium to cause this relocalization. Moreover, this previous study found that
even in the presence of the myristoylation site and PB1-3, gravin localization at the cell
periphery was severely hindered by the deletion of a fourth putative calmodulin binding
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domain (CB4) (Schott & Grove, 2013), a region which contains a 1-5-10 consensus motif
for CaM interaction (Rhoads & Friedberg, 1997). To test the role of this CaM consensus
sequence within the CB4 domain in the membrane localization of gravin, we used sitedirected mutagenesis to substitute the 1-5-10 amino acids in this sequence for alanine as
seen in Fig. IV-5A, similar to the strategy used by several other investigators (see Ahn,
Lim, Cook, & McDonald, 2004; Fancy et al., 2014; Suever, Chen, McDonald, & Song,
2008). Expressing this mutant construct, termed (mutCB4) gravin-EGFP, revealed a
dramatically reduced membrane localization compared to WT gravin-EGFP. Membrane
localization of (mutCB4) gravin-EGFP was not different compared to (ΔCB4) gravinEGFP (Fig. IV-5B). From these results, we conclude that the 1-5-10 amino acids within
gravin’s CB4 domain are required for normal membrane localization. This suggests a
novel role for CaM in supporting gravin localization at the membrane, which contrasts
with previous reports showing that CaM promotes gravin relocalization away from the
membrane by binding to PB1-3.
Using the (mutCB4) gravin-V5/His construct, we sought to define the importance
of gravin localization at the membrane in gravin’s ability to impact subcellular PKA
activity both at the plasma membrane and within the cytosol. In figure IV-6,
representative confocal micrographs of AN3 CA cells transfected with gravin-V5/His
constructs and immunolabeled for gravin illustrate that while full-length (WT) gravin
strongly localized along the cell periphery, (mutCB4) gravin did not. In AN3 CA cells
expressing plasma membrane AKAR3-CAAX, gravin-V5/His expression potentiated
forskolin-stimulated PKA activity compared to control cells with no gravin, but this
increase was not observed in cells expressing (mutCB4) gravin-V5/His (Fig. IV-6A-B).
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Similarly, in cells expressing cytosolic AKAR3-NES, the presence of gravin-V5/His
reduced forskolin-stimulated PKA activity in the cytosol compared to control cells with
no gravin, but this suppression was not observed in cells expressing (mutCB4) gravinV5/His (Fig. IV-6C-D). These results demonstrate that alterations in gravin localization
have profound effects on subcellular PKA activity, both at the plasma membrane and in
the cytosol.
Thapsigargin Causes Gravin Redistribution and Inhibits
Gravin-Mediated Potentiation of Plasma Membrane PKA Activity.
Intracellular calcium elevation causes the redistribution of gravin away from the
plasma membrane and into the cytosol, and this redistribution also triggers the
relocalization of PKA away from the cell periphery (Schott & Grove, 2013; Tao et al.,
2006). In light of this, we sought to determine whether calcium-mediated gravin
redistribution would impact the ability of gravin to potentiate PKA activity at the plasma
membrane. To test this, we pre-treated AN3 CA cells expressing AKAR3-CAAX with 10
μM thapsigargin, a calcium-elevating agent which causes gravin redistribution. AN3 CA
cells co-expressing gravin-V5/His showed elevated PKA activity compared to control
cells with no gravin when treated with forskolin without pretreatment with thapsigargin.
However, 30 minute pre-treatment with thapsigargin abolished gravin’s ability to
potentiate forskolin-stimulated PKA activity. Pre-treatment with thapsigargin in cells
with no gravin showed no significant difference in forskolin-stimulated PKA activity,
confirming that the effect of thapsigargin on plasma membrane PKA activity was gravindependent (Fig. IV-7A-B). In Figure IV-7C, representative micrographs of AN3 CA cells
expressing gravin-EGFP demonstrate the impact of thapsigargin pretreatment on gravin
distribution. To confirm that gravin redistribution had also occurred in experiments
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represented by Figure IV-7A-B, coverslips were immunofluorescently labeled for gravin
after these experiments. As seen in Figure IV-7D, the percentage of cells showing gravin
localization at the cell periphery dropped dramatically with thapsigargin pretreatment.
Overall these results demonstrate that calcium-mediated gravin redistribution alters
plasma membrane PKA activity and supports the hypothesis that gravin can mediate
crosstalk between calcium and cAMP-dependent signaling pathways.
Discussion
In the current study, we investigated the role of gravin in shaping
compartmentalized PKA activity and in mediating crosstalk between Ca2+ and cAMPdependent signaling pathways. We report that the expression of gravin potentiated PKA
activity at the plasma membrane and reduced PKA activity in the cytosol. The impact of
gravin on membrane and cytosolic PKA activity depended on both gravin-PKA
interaction and gravin-membrane interaction. This was evident from the finding that
mutant gravin constructs that lack PKA interaction ([ΔPKA] gravin) or normal membrane
localization ([mutCB4] gravin) had no impact on plasma membrane or cytosolic PKA
activity. In addition, redistribution of gravin away from the cell periphery with
thapsigargin, a calcium-elevating agent, also inhibited the potentiation of plasma
membrane PKA activity by gravin. These results support the hypothesis that gravin
mediates cross-talk between calcium and cAMP-dependent signaling pathways and may
provide mechanistic insight into gravin’s role in health and disease.
In the current study, gravin increased forskolin-stimulated PKA activity at the
plasma membrane while reducing cytosolic PKA activity, and this effect required both
PKA interaction and localization at the cell periphery. This suggests that gravin mediates
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its impact on subcellular PKA activity by targeting PKA to the plasma membrane and
sequestering PKA from the cytosol. The notion that gravin targets PKA to the cell
periphery is in line with its characterization as an AKAP and has been clearly
demonstrated in previous studies (Schott & Grove, 2013; X. Yan et al., 2009). However,
the putative sequestration of PKA away from the cytosol is not well defined. Assuming a
fixed concentration of PKA, it is logical that AKAP-mediated targeting of PKA to one
compartment would to some degree subtract PKA concentrations in other compartments.
In fact, this sequestration phenomenon was proposed in an early study of AKAP79
overexpression in HEK293 cells (Ndubuka, Li, & Rubin, 1993). A recent study by Su et
al. (2013) also showed that rodent gravin (also called SSeCKS) reduces FAK
phosphorylation presumably through the sequestration of Src to lipid rafts and away from
FAK-associated complexes (Su et al., 2013). Gravin interaction with cyclin D1 was also
shown to sequester cyclin D1 away from the nucleus in mouse glomerular parietal
epithelial cells (Burnworth et al., 2012). The current study raises the intriguing possibility
that gravin may reduce PKA activity in other cellular compartments through PKA
sequestration at the plasma membrane. However, future experiments using endogenous
gravin knockdown and/or computational modeling will be required to validate the
efficacy of this phenomenon at normal physiologic levels of gravin expression.
The finding that forskolin-stimulated PKA phosphorylation of AKAR3 constructs
targeted to the plasma membrane was elevated with the expression of gravin-V5/His
suggests that gravin may facilitate PKA phosphorylation of a wide range of membranetargeted substrates. Although remarkably little is known about gravin’s role in targeting
specific PKA substrates, several lines of evidence indicate that gravin participates in
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PKA-dependent signaling events at or near the membrane. Tao et al. (2003) showed that
gravin-PKA interaction facilitates PKA phosphorylation of both β2-adrenergic receptor
(β2AR) and gravin itself. Gravin and β2AR phosphorylation enhances their physical
interaction with one another, which regulates receptor resensitization following
isoproterenol-induced desensitization (Tao et al., 2003). A study by Havekes et al. (2012)
also showed reduced β2AR phosphorylation in gravin knockdown mice and implicated a
role for gravin in G protein switching (Havekes et al., 2012), which is another
consequence of β2AR phosphorylation by PKA (Daaka, Luttrell, & Lefkowitz, 1997).
Gravin may also target the phosphorylation of PDE4D, a PKA-enhanced
phosphodiesterase that binds to gravin (Raymond, Wilson, Carter, & Maurice, 2007;
Willoughby et al., 2006b). The finding that AKAR3 constructs targeted to the membrane
show increased phosphorylation in the presence of gravin expands the possible range of
PKA substrates targeted by gravin in this compartment. It would be interesting to explore
the impact of gravin expression on other known PKA targets at or near the plasma
membrane such as ion channels (Brown & Yule, 2010; Dai, Hall, & Hell, 2009; Swope,
Moss, Raymond, & Huganir, 1999) and cytoskeletal regulators (Howe, Baldor, & Hogan,
2005; Y. Wang et al., 2006).
While the current study demonstrates that gravin potentiates PKA activity at the
plasma membrane, our results also suggest that this potentiation is present within both
raft and non-raft membrane microdomains. Evidence for this was seen in gravin’s ability
to direct the phosphorylation of two membrane-associated AKAR3 constructs: AKAR3CAAX and Lck-AKAR3. AKAR3-CAAX contains a C-terminal prenylation domain that
has been shown to localize preferentially at non-raft microdomains, whereas Lck-
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AKAR3 contains a myristoylated and palmitoylated N-terminal domain has been shown
to target ordered lipid domains known as membrane rafts (Agarwal et al., 2014; Allen &
Zhang, 2006; Melkonian et al., 1999). While plasma membrane microdomains represent
highly dynamic compartments, some evidence suggests that protein-protein interactions
within these compartments can be exclusive (Depry et al., 2011; Gao et al., 2011;
Zacharias et al., 2002). How then could gravin facilitate PKA dependent phosphorylation
activity in different membrane microdomains? One possibility could be via dissociation
and diffusion of C subunits from R subunit dimers as described by the classical model of
PKA activation. However, serious challenges to this dissociation model have been
outlined in recent years. First, cAMP binds to PKA with low diffusion constant on the
order of nanomolars, so it is not likely to be readily turned over in cells (Poppe et al.,
2008). In addition, Smith et al. (2013) show that AKAP18-PKA complexes – similar to
gravin-PKA in that both involve RIIα – retain the catalytic subunit (PKAc) even after
isoproterenol stimulation and subsequent elevation of PKA activity. In fact, Smith et al.
(2013) further showed that a flexible linker domain on RIIα works to constrain PKAc to
substrates within a ~16 nanometer radius (F. D. Smith et al., 2013). In addition to these
important studies, the current study also challenges the PKAc dissociation model, evident
in the finding that gravin was able to reduce cytosolic PKA activity through interaction
with PKA and with the plasma membrane. This finding would be difficult to explain
were PKAc to dissociate into the cytosol following forskolin treatment (an example of
subcellular PKAc dissociation is seen in Martin, Deerinck, Ellisman, Taylor, & Tsien,
2007). Therefore, the extent of gravin-directed PKA activity at the membrane may more
likely due to the localization of gravin within both raft and non-raft microdomains. To be
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sure, the localization of gravin within these microdomains is currently not well
understood; however its N-myristoylation motif suggests a preferred localization within
membrane rafts. This is in part supported by a study by Choi et al (2008), which showed
that plasma membrane cholesterol extraction in SNU-449 cells caused gravin
redistribution away from the cell periphery to intracellular vesicles (M. C. Choi, Lee,
Kim, Lee, et al., 2008). In a more recent study, Su et al (2013) showed that exogenous
rodent gravin, also called SSeCKS, was found in caveolin-rich membrane fractions
corresponding to membrane rafts. However, Su et al. also showed moderate gravin
labeling in “lighter” membrane fractions which supports the notion that gravin may
localized within both membrane microdomains, at least in exogenous expression models
(Su et al., 2013). The current study also uses exogenous gravin expression, so it is unclear
whether levels of endogenous gravin would result in a similar localization within both
raft and non-raft membrane microdomains, or facilitate the phosphorylation of both
membrane-targeted AKAR3 constructs as observed in the current study. Nonetheless, if
the breadth of PKA activity across membrane microdomains is proportional to the level
of gravin expression in cells, this may serve as an important regulatory mechanism for
PKA phosphorylation at the plasma membrane. This would be a fascinating topic of
further research, especially given that gravin expression is highly regulated in cells under
various physiological conditions such as cancer (reviewed in Gelman, 2012),
inflammation (Kitamura et al., 2002; Sun, Cheng, Liu, Xiao, et al., 2007; Q. H. You et
al., 2010), tissue injury/stress (Chen et al., 2008; Dolinay et al., 2006; Higgins et al.,
2003), and hypoxia (Wasenius et al., 2003; Weissmuller et al., 2014).
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The finding that gravin localization at the cell periphery is impaired by the
mutation of a consensus binding motif for Ca2+/calmodulin (CaM) within the CB4
domain suggests a novel role for CaM interaction with gravin. A previous study by Tao et
al. (2006) suggests that CaM plays a role in relocalization of gravin to the cytosol upon
calcium elevation by binding to the membrane-associated polybasic domains, PB1-3 (Tao
et al., 2006). More recently, we demonstrated that a gravin mutant missing PB1-3 still
underwent calcium-dependent redistribution identical to that of full-length gravin, which
suggests that the role of CaM in mediating gravin redistribution is more complex than
previously thought. In fact, deletion of gravin’s CB4 domain – a fourth putative CaM
binding domain located downstream of gravin’s polybasic domains – caused a significant
reduction in the basal localization of gravin the cell periphery even in the absence of
calcium elevation (Schott & Grove, 2013). Since CaM has been linked to gravin
redistribution, we proposed in the previous study that deletion of the CB4 domain might
mimick a CaM-gravin interaction and prevent gravin from associating with the plasma
membrane. However, as the current study indicates, a gravin construct with mutations to
the CaM-binding amino acid sequence within the CB4 domain caused a similar reduction
in membrane localization as CB4 deletion, suggesting that CaM-CB4 interaction
promotes gravin localization at the plasma membrane under basal conditions. Thus, while
CaM binding to gravin may regulate the dissociation of gravin from plasma membrane,
possibly via an interaction with polybasic domains 1-3, CaM binding may also regulate
the association of gravin at the membrane through binding to CB4. At the moment, it is
not clear how CaM binding to the CB4 domain might support membrane association. One
possibility is that the CB4 domain may support the myristoylation site in binding to the
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membrane through an as yet unknown mechanism. Previous work by us shows that the
myristoylation site is sufficient to retain normal membrane localization in the absence of
a region containing the polybasic domains (X. Yan et al., 2009), but it is not sufficient for
normal gravin-membrane localization in the absence of a region containing both the
polybasic domains and CB4 (Schott & Grove, 2013). Perhaps in the absence of CaMCB4 binding, the conformation of gravin’s tertiary structure renders the myristoylation
site and PB1-3 inaccessible to membrane phospholipids. It is also interesting that the CB4
domain (a.a. 669–693) lies directly upstream of three PKA-phosphorylation sites (ser696698) which have been shown by Tao et al. (2003) to enhance gravin’s association with
β2AR. It is possible that CaM binding to CB4 may influence either the
phosphorylation/dephosphorylation of serines 696-698 or the interaction of these sites
with other proteins. Future studies could investigate the importance of gravin’s CB4
domain in serine 696-698 phosphorylation and in β2AR interaction to gain clues into the
role of this domain in membrane localization.
Demonstration that thapsigargin pre-treatment abolished gravin’s ability to
potentiate PKA activity at the plasma membrane indicates a role for gravin in regulating
cross-talk between calcium- and cAMP-dependent signaling pathways. Several lines of
evidence clearly show that although gravin is distributed at the plasma membrane under
basal conditions, gravin redistributes away from the membrane in response to PKC
activation (Lin et al., 1996a; Piontek & Brandt, 2003) and/or cytosolic Ca2+ elevation
(Tao et al., 2006), both of which are also shown to cause the redistribution of PKA away
from the cell periphery (Schott & Grove, 2013; X. Yan et al., 2009). Despite the
understanding that gravin redistribution alters PKA localization, the impact of gravin
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redistribution on subcellular PKA activity has not been demonstrated until now. In the
current study, pre-treatment with thapsigargin caused the redistribution of gravin and
prevented gravin-mediated potentiation of PKA activity at the plasma membrane.
Importantly, thapsigargin pre-treatment had no significant impact on membrane PKA
activity in the absence of gravin, demonstrating that the impact of thapsigargin on
membrane PKA activity was gravin-dependent and likely mediated by gravin
redistribution. The notion that calcium elevation impacts PKA activity through changes
in gravin distribution represents a novel mode of calcium/cAMP crosstalk. It is well
documented that crosstalk between these two second messenger pathways has broad
physiological relevance, and several pathways have been described. Calcium-dependent
signaling is known to regulate cAMP production through various adenylyl cyclase
isoforms, but calcium can also regulate cAMP degradation by stimulating type 1
phosphodiesterase (reviewed in Halls & Cooper, 2011). The current study describes a
mechanism of Ca2+/cAMP crosstalk downstream of cAMP production and degradation
that operates through the spatial regulation of PKA by gravin. This lays groundwork for
future studies to investigate the impact of gravin-mediated calcium/PKA crosstalk in
vivo. For example, based on the current study we predict that calcium impacts not only
β2AR phosphorylation, but also plasma membrane PKA activity operating downstream
of receptor activation. This may be important particularly in hippocampal neurons where
gravin was shown to phosphorylate β2AR and regulate learning and memory (Havekes et
al., 2012). Gravin is also shown to regulate cellular migration, a phenomenon which
relies heavily on the compartmentalization of PKA at the leading edge, and also on
calcium/PKA crosstalk (Howe, 2011). Since our knowledge of gravin-dependent PKA
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phosphorylation targets remains somewhat limited, it is hard to predict the precise impact
of gravin in the context of calcium signaling. Proteomic knowledge of PKA substrate
dynamics in the presence and absence of gravin may be critical in future studies.
Conclusions
We report here that gravin-V5/His expression impacted PKA activity at the
plasma membrane and in the cytosol. This effect was seen in response to forskolin
treatment, which showed higher levels of PKA activity at the plasma membrane and
lower levels of PKA activity in the cytosol when gravin was expressed. Experiments
using mutant gravin constructs revealed that this impact on plasma membrane and
cytosolic PKA activity was dependent on gravin’s interaction with PKA and localization
at the cell periphery. Pretreatment with thapsigargin triggered the redistribution of gravin
away from the cell periphery and inhibited gravin-V5/His from increasing forskolinstimulated PKA activity at the plasma membrane. Our data shows that gravin expression
may have profound effects on subcellular PKA activity and supports the hypothesis that
gravin facilitates crosstalk between Ca2+ and cAMP-dependent signaling pathways.
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Figure IV-1.

Quantification of PKA dynamics with AKAR3. Fluorescent images show
the distribution of three AKAR3 constructs that contain a targeting
sequence for the cytosol (NES), non-raft plasma membrane (CAAX), or
membrane rafts (Lck). Forskolin caused a drop in CFP fluorescence and
an increase in YFP fluorescence as imaged through CFP and FRET
channels, respectively. FRET intensity was corrected for CFP crossover
(44%) at each time point. The normalized ratio of FRET/CFP intensity
was then plotted over time, and the fold increase was calculated by
dividing the maximal ratio value after treatment (Rmax) by the average
ratio value prior to treatment (R0). Graph C represents the mean fold
increase in each of the AKAR3 constructs after 10 μM forskolin treatment.
Scale bar = 10 μm; cells were incubated in 10 µM IBMX for 30 minutes
prior to forskoliln treatment.
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Figure IV-2.

Gravin-V5/His expression alters subcellular PKA activity. AN3CA cells
were co-transfected with gravin-V5/His and with AKAR3 constructs
containing targeting sequences for non-raft membrane (CAAX),
membrane raft (Lck), or cytosolic (NES) localization. Representative
fluorescent images show the distribution the AKAR3 constructs.
Expression of gravin increased forskolin-mediated PKA activity in both
non-raft (A,B), and raft (C,D) membrane compartments. Conversely,
gravin reduced PKA activity in the cytosol (E,F). Mann-Whitney Rank
Sum tests revealed significant differences between the mean fold increases
of each treatment. Asterisks denote p < 0.05. Scale bar = 10 μm ; cells
were incubated in 10 μM IBMX for 30 minutes prior to forskolin
treatment.
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Figure IV-3.

PKA RII-ECFP was localized to the cell periphery in AN3CA cells only
when full-length WT gravin was present. Graph A shows that 39% of cells
expressing PKA RII-ECFP showed ECFP localization at the cell periphery
when co-transfected with WT gravin-V5/His. No cells showed PKA RIIECFP localization at the cell periphery when co-transfected with (ΔPKA)
gravin-V5/His, or when expressed in cells containing no gravin. Graph B
shows the % co-transfection of PKA RII-ECFP positive cells with and
without gravin-V5/His constructs. PKA-RII-ECFP positive cells showed a
high rate of co-transfection with gravin-V5/His constructs as indicated by
immunofluorescence labeling with a gravin antibody (94% with WT
gravin-V5/His; 95% with (ΔPKA) gravin-V5/His), but cells transfected
with PKA RII-ECFP only showed no immunofluorescence labeling the
gravin antibody.
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Figure IV-4.

Forskolin-stimulated PKA activity at the plasma membrane (AKAR3CAAX) and cytosol (AKAR3-NES) in AN3CA cells co-expressing
AKAR3 and either WT or (ΔPKA) gravin-V5/His. Graphs A,B show that
while gravin expression caused an increase in forskolin-stimulated PKA
activity at the plasma membrane, this increase was not observed in cells
expressing ΔPKA gravin. Graphs C,D show that the gravin-mediated
suppression of cytosolic PKA activity was not observed in cells expressing
ΔPKA gravin. One-way ANOVA with Holm-Sidak post hoc tests revealed
significant differences between the mean fold increase as indicated by
asterisks. Representative confocal micrographs show the distribution of
transfected gravin-V5/His constructs in fixed cells immunolabeled with a
gravin antibody. Scale bar = 10 μm. Cells were incubated in 10 μM IBMX
for 30 minutes prior to forskolin treatment.
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Figure IV-5.

Role of CB4 domain in subcellular gravin localization. Part A illustrates
the sequence and location of gravin’s CB4 domain downstream of the
membrane targeting regions (myr, PB1-3). Amino acids shown in red
comprise a calmodulin-binding consensus sequence and were substituted
for alanine. Mutagenesis was confirmed by HindIII restriction digest (not
shown). In graph B, either mutation or deletion of the CB4 domain caused
a significant reduction in membrane localization compared to WT gravin.
(ANOVA with Holm–Sidak post-hoc test; asterisks denote significant
differences; NS, not significant). Representative fluorescent images show
the localization of these constructs in AN3CA cells. Scale bar = 20 μm.
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Figure IV-6.

Forskolin-stimulated PKA activity at the plasma membrane (AKAR3CAAX) and cytosol (AKAR3-NES) in AN3CA cells co-expressing
AKAR3 and either WT or (mutCB4) gravin. Graphs A,B show that while
gravin expression caused an increase in forskolin-stimulated PKA activity
at the plasma membrane, this increase was not observed in cells
expressing mutCB4 gravin. Graphs C,D show that the gravin-mediated
suppression of cytosolic PKA activity was not observed in cells expressing
mutCB4 gravin. One-way ANOVA with Holm-Sidak post hoc tests
revealed significant differences between the mean fold increase as
indicated by asterisks. Representative confocal micrographs show the
distribution of transfected gravin-V5/His constructs in fixed cells
immunolabeled with a gravin antibody. Scale bar = 10 μm. Cells were
incubated in 10 μM IBMX for 30 minutes prior to forskolin treatment.
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Figure IV-7.

Thapsigargin triggers gravin redistribution and abolishes gravin-mediated
elevation in plasma membrane PKA activity. Graphs A,B show that gravin
expression caused an increase in forskolin-stimulated PKA activity at the
membrane, but this increase was not observed in cells expressing gravin
but pretreated with the calcium-elevating agent thapsigargin (10 µm) for
30 min. Thapsigargin pretreatment had no effect on forskolin-stimulated
PKA activity in the absence of gravin. One-way ANOVA on ranks with
Kruskal-Wallis post hoc showed significant differences between
treatments as indicated by asterisks. In part C, representative fluorescent
images illustrate the redistribution of gravin-EGFP away from the plasma
membrane by thapsigargin. Gravin-V5/His redistribution was confirmed
after FRET experiments by quantifying the percentage of cells showing
gravin localization at the membrane, shown in box plot represented in
graph D. Scale bar = 10μm.
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CHAPTER V
DISCUSSION
The goal of the current study was to investigate the hypothesis that gravin
mediates crosstalk between calcium and cAMP dependent signaling pathways by
translocating from the plasma membrane to the cytoplasm in response to intracellular
calcium elevation. This study demonstrated that gravin undergoes redistribution in
response to treatment with the calcium-elevating agents ionomycin, thapsigargin, and
ATP. These calcium elevating agents triggered not only the redistribution of gravin but
also the loss of compartmentalized PKA at the cell cortex. Calcium-mediated gravin
redistribution did not require the calmodulin-binding polybasic domains (PB1-3), but a
fourth calmodulin binding domain (CB4) was shown to be important for membrane
localization under basal conditions and suggests that calmodulin plays a complex role in
regulating gravin-membrane interaction. Gravin-membrane interaction was shown to be
important for PKA localization and for compartmentalized PKA activity, as seen in
studies using the PKA FRET biosensor AKAR3. These studies determined that gravin
expression potentiates plasma membrane PKA activity but suppresses cytosolic PKA
activity. Gravin’s impact on membrane and cytosolic PKA activity were lost in cells
expressing gravin constructs that either lacked the PKA binding domain or were inhibited
in binding to the membrane. In addition, thapsigargin pretreatment, which caused gravin
redistribution, prevented gravin-mediated potentiation of PKA activity at the plasma
membrane. By demonstrating the impact of calcium-mediated gravin redistribution on
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PKA localization and subcellular activity, these studies support the hypothesis that
gravin mediates crosstalk between calcium and cAMP dependent signaling pathways.
Gravin-mediated crosstalk between calcium and cAMP-dependent signaling
outlined in the current study represents a novel mode of crosstalk between these two
signaling pathways. The influence of calcium on cAMP-dependent signaling is well
understood to occur in the regulation of cAMP levels themselves (Reviewed by Halls &
Cooper, 2011). Production of cAMP begins with G-protein coupled receptors (GPCRs)
that associate with trimeric G-proteins containing the stimulatory α-subunit, αs. Upon
GPCR activation, Gαs dissociates from βγ subunits and activates adenylyl cyclase (AC)
enzymes, which then convert ATP to cAMP. Adenylyl cyclase activity (and therefore
cAMP production) can be influenced by calcium-dependent signaling mediators which
target certain isoforms in either a stimulatory or inhibitory manner. For example,
Ca2+/calmodulin (CaM) stimulates three of the ten known adenylyl cyclase isoforms,
AC1, AC3, and AC9, whereas AC5 and AC6 are inhibited by CaM. Other adenylyl
cyclase isoforms are further regulated by calcium-dependent phosphorylation by CaMdependent kinases (CaMK) and dephosphorylation by CaM-dependent phosphatases
(CaN). For example, AC1 and AC3 are inhibited by CaMK phosphorylation, and AC9 is
inhibited by CaN dephosphorylation. In addition to calcium’s impact on cAMP
production, however, calcium-dependent signaling mediators also regulate cAMP
degradation. For example, CaM is known to stimulate phosphodiesterase type 1, an
enzyme that hydrolyzes cAMP back to AMP. It is clear from the current literature that
calcium plays a complicated role in regulating intracellular cAMP levels, and the current
study adds to this by showing that calcium exerts addition control over cAMP-dependent
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signaling downstream of cAMP production/degradation by regulating the interaction of
PKA with its targets (Fig. V-1). We report that this mechanism occurs through the
calcium-mediated redistribution of gravin. In our studies, gravin targeted PKA to the cell
periphery and potentiated forskolin-stimulated PKA activity at the plasma membrane. In
response to calcium elevation, gravin redistribution caused the relocalization of PKA
away from the cell periphery and also inhibited the potentiation of plasma membrane
PKA activity by gravin.

1
3

2

Figure V-1.

Ca2+ crosstalk with cAMP signaling pathways occurs by (1)
positive/negative regulation of adenylyl cyclases which produce cAMP,
(2) regulation of phosphodiesterases that hydrolyze cAMP, and (3)
regulation of cAMP-dependent protein kinase (PKA) interaction with
substrate proteins, as evidenced by the current study.
Role of Calmodulin in Gravin-Mediated Ca2+/cAMP Crosstalk

Future studies will be required to fully understand the mechanism behind calcium
-mediated gravin redistribution, but our results and others suggest a role for calmodulin in
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this event. Tao et al. (2006) first asserted that CaM causes gravin redistribution by
binding to the membrane associating polybasic domains (PB1-3) and thereby reversing
their electrostatic interaction with the plasma membrane. However, a later study from our
laboratory showed that a mutant gravin construct missing PB1-3 was still localized at the
plasma membrane identical to full-length gravin due to the N-myristoylation site (X. Yan
et al., 2009). This raised the interesting possibility that this mutant construct missing
PB1-3 would not interact with CaM and would therefore remain at the plasma membrane
upon calcium elevation. In the current study, we discovered that this was not the case.
Even in the absence of PB1-3, gravin localized to the plasma membrane and translocated
to the cytosol upon calcium elevation at an identical rate to that of full-length gravin,
suggesting that the polybasic domains are in fact not necessary for calcium-mediated
gravin redistribution. This result also supports another interesting finding by Yan et at.
(2009) which showed that this same ΔPB1-3 construct also underwent PKC-mediated
redistribution, despite a previous assertion that PKC phosphorylation of the polybasic
domains mediates gravin redistribution. In search for an explanation for these results, we
came to find that the ΔPB1-3 gravin mutant construct does retain a fourth putative
calmodulin binding domain downstream of PB1-3. This region, which we have termed
CB4, was first identified by Tao et al. (2006) and was reported to have no affinity for
phospholipid vesicles. We therefore reasoned that the ΔPB1-3 grain mutant underwent
calcium-mediated redistribution because of CaM interaction with the downstream CB4
domain. To test this assertion, we generated a gravin mutant missing PB1-3 and CB4, but
surprisingly this mutant did not localize to the plasma membrane under basal conditions
in a manner that was sufficient to measure it’s redistribution upon calcium elevation. In
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fact, both deletion of CB4 and mutation of the putative calmodulin binding sequence
within the CB4 domain caused a dramatic reduction in gravin localization at the cell
periphery. This finding suggests that while calmodulin interaction with PB1-3 could
promote the dissociation of these domains from the plasma membrane, calmodulin
interaction with CB4 promotes the association of gravin with the plasma membrane. This
may provide insight not only into the membrane localization of gravin, but also into
calcium mediated gravin redistribution.
It is possible that the function of gravin’s CB4 domain is to support the membrane
binding activity of the myristoylation site. Evidence for this comes from the finding that
ΔPB1-3 gravin mutant is localized at the membrane, but the ΔPB1-3,CB4 gravin mutant
is not, even though both of these mutant constructs contain the N-terminal myristoylation
sequence. To put it another way, the myristoylation site is sufficient for membrane
localization, but only when the CB4 domain is present. Although myristoyl lipid anchors
are involved in the localization of proteins to plasma membranes, they are reported to
have relatively weak binding energy by themselves and are thus supported either by
additional lipid anchors like palmityol groups or by interactions with other membranebound or transmembrane proteins (Resh, 1999). Gravin does not contain any
palmitoylation sequences, but the latter notion is quite possible since the CB4 domain
(a.a. 669-684) falls within the β2AR binding region (a.a. 652-938) described by Tao et al.
(2003). Based on this, it’s possible that the CB4 domain itself and/or CaM binding to
CB4 could play a role in facilitating gravin’s interaction with β2AR, thereby supporting
gravin’s localization at the cell periphery. This is an exciting prospect that could be tested
in several ways. The first would be to determine whether the interaction between full-
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length gravin and β2AR receptor is different than that of (mutCB4) gravin or (ΔCB4)
gravin. Next, it should be confirmed whether calmodulin binds to CB4 and if this is
important in gravin’s interaction with β2AR. It would also be useful to explore gravin
localization and interaction with β2AR receptor in living cells under calmodulin
knockdown and overexpression conditions, or with pharmacological inhibitors of
calmodulin such as Ophobolin-A, which prevents calmodulin from interacting with other
proteins by covalently bonding to calmodulin’s hydrophobic pocket. Gravin localization
could be also assessed under β2AR receptor knockdown and overexpression conditions.
Finally, it would be interesting to generate a peptide corresponding to the CB4 domain to
serve as a competitive inhibitor for calmodulin interaction with this region. One could
assess the impact of this peptide on (A) gravin localization at the cell periphery, and (B)
gravin’s interaction with β2AR. I predict that a CB4 peptide would competitively
interfere with calmodulin binding to gravin and thus inhibit gravin’s localization at the
plasma membrane and possibly gravin’s interaction with β2AR. This inhibitor peptide
may even serve as a means for therapeutic intervention in regulating calcium and cAMP
crosstalk in cells expressing gravin, which could be explored in vascular endothelial
disorders and/or hippocampal learning and memory.
Ca2+/cAMP Crosstalk in Vascular Function.
In the context of vascular endothelial cell function, unpublished work from our
lab shows that gravin promotes cellular migration in a scratch wound healing model. In
addition to this, gravin is concentrated at the leading edge of microvascular endothelial
cell lamellipodia along with RhoA and F-actin. In light of the current study, gravinmediated Ca2+/cAMP crosstalk may be a promising avenue for research in the context of
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endothelial cell migration. A review written by Alan Howe (2011) discusses the critical
importance of calcium and PKA crosstalk in migrating cells, particularly with regard to
localized calcium transients in at the leading edge (Howe, 2011). These transients are in
part mediated by stretch-activated calcium channels (SACC) which become active in
response to mechanosensation, causing transient extracellular calcium influx. TRPM7,
for example, is known to produce calcium transients known as “flickers” in leading edge
lamellipodia that are important for cellular migration. TRPC1 is another leading edge
SACC that regulates cellular chemotaxis through lamellipodial calcium gradients.
Finally, TRPV4 mediated calcium signaling is linked to cytoskeletal remodeling. The
possible link between these SACC-mediated pathways and gravin in the context of
endothelial cell migration are completely unknown but would make a fascinating subject
for further research. It is possible that gravin’s localization at the leading edge is
mechanosensitive in response to SACC-mediated calcium entry. I predict that SACC
channel activation would cause the transient redistribution of gravin away from the point
of calcium influx, and this would additionally impact the interaction of PKA with
downstream targets. Some of these targets may be cytoskeletal effector proteins such as
RhoA, which is distributed at the leading edge with gravin in microvascular endothelial
cells. Also, it is possible that a calmodulin-interfering peptide, such as the CB4 domain,
could be generated to regulate gravin localization at the cell periphery and perhaps be
used as a therapeutic agent to regulate endothelial cell migration. Given the clear link
between gravin and endothelial barrier function and angiogenesis, this might create
additional avenues for treatment of diseases such as stroke or tumor growth.

101

Another component of the vasculature that readily expresses gravin is smooth
muscle cells, which utilize calcium signaling to regulate cytoskeletal organization and
contractility. Bruce et al. (2003) reports an interesting smooth muscle phenomenon in
which contractility and relaxation are both regulated by calcium but depend entirely on
the shape of the calcium signal. For example, calcium sparks – localized calcium
transients – mediate smooth muscle cell contractility while more global calcium signals
mediate relaxation (Bruce, Straub, & Yule, 2003). While smooth muscle cells readily
express gravin, the impact of gravin on smooth muscle function is poorly understood. It
would be interesting to observe whether calcium sparks vs. whole cell calcium gradients
impact gravin distribution, PKA distribution, and PKA activity/phosphorylation of
downstream substrates.
Gravin is also present in cardiomyocytes of the heart, and knockdown of gravin in
mice is shown to enhance cardiac contractility (Guillory et al., 2013). Given the central
importance of calcium signaling in cardiac myocytes, it is possible that gravin mediates
its effect on cardiac contractility in part through Ca2+/cAMP crosstalk. Future
experiments could be done to determine the difference in phosphorylation states of PKA
substrates within wild-type versus gravin knockdown hearts, and assess how calcium
signaling in cardiac myocytes may regulate this phosphorylation in a gravin-dependent
manner. In addition, calcium signaling in cardiac myocytes may regulate β2AR receptor
sensitivity by affecting its association with gravin.
Role of Gravin in GPCR Crosstalk
The current study suggests that gravin intersects with GPCR signaling in a
number of ways. This line of investigation also represents a promising next step for
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further research. This study showed that receptor-mediated signaling linked to [Ca2+]i
elevation and PKC activation caused gravin and PKA redistribution. In addition, gravin
redistribution was shown to regulate not only PKA localization, but gravin-mediated
potentiation of PKA activity the cell periphery. Given these findings, it is reasonable to
hypothesize that (1) gravin potentiates Gs-coupled GPCR signaling at the plasma
membrane, (2) Gq-coupled GPCRs impact cAMP-dependent signaling through gravin
redistribution, and therefore (3) gravin mediates crosstalk between Gq-coupled and Gscoupled GPCRs.
Evidence that gravin may potentiate GPCR-stimulated PKA activity at the plasma
membrane comes from the demonstration that gravin directs PKA localization at the cell
periphery through its PKA-binding domain (also shown by X. Yan et al., 2009) and that
gravin potentiates plasma membrane PKA activity upon treatment with forskolin, an
agent which raises cAMP levels by stimulating adenylyl cyclase. GPCRs coupled to Gs
are known to stimulate adenylyl cyclase and raise cAMP levels, suggesting that these
receptors may also be subject to gravin-mediated potentiation of PKA activity at the
plasma membrane. An obvious context for the investigation of this hypothesis would be
within β2AR receptor signaling, since gravin is known to physically interact with this Gscoupled receptor (G. F. Fan et al., 2001; Shih et al., 1999b). This, however, brings up an
interesting question: Does gravin impact PKA activity in only certain Gs-coupled GPCR
pathways or does it regulate a wide array of Gs-coupled GPCR pathways? This question
could be investigated by treating cells with different Gs-coupled GPCR agonists in cells
expressing AKAR3 biosensors in the presence and absence of gravin. This approach
could also be investigated in the context of a physiological output, such as endothelial
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barrier function. A recent study by Weissmuller et al. (2014) showed that gravin supports
endothelial barrier formation in response to treatment with PKA-stimulating GPCR
agonists albuterol (β-adrenergic agonist) and NECA (adenosine receptor agonist).
Perhaps gravin accomplishes this by potentiating PKA activity at the plasma membrane
in response to these agonists.
In addition to gravin’s potential impact on Gs-coupled GPCR systems, it is also
likely that Gq/11-coupled GPCRs may cause gravin redistribution, thereby altering PKA
localization and compartmentalized PKA activity. Evidence for this comes from the
findings that ATP caused gravin and PKA redistribution in HEC1A cells (Fig. III-8), and
that gravin redistribution required both calcium elevation and PKC activity (Fig. III-7).
Since ATP-mediated gravin redistribution was unaffected in the absence of extracellular
calcium, it is likely that this change occurred through P2Y receptors, many of which are
coupled to Gq/11. Given that Gq/11-coupled GPCRs are known to cause both PKC
activation and [Ca2+]i elevation from intracellular stores through phospholipase C
activity, it is possible that other Gq/11-coupled GPCRs also cause gravin redistribution
and alter PKA localization. To test this, one could treat cells expressing gravin-EGFP
with a variety of agonists that target Gq/11-coupled GPCRs and measure the impact on
gravin distribution. These experiments could also be applied to AKAR3-expressing cells
in the presence and absence of gravin to measure the impact of GPCR-mediated gravin
redistribution on forskolin-stimulated PKA activity at the plasma membrane (see Fig. IV5). Going back to the example of endothelial barrier function, it’s interesting to note that
some of the most potent agonists for endothelial permeability – thrombin, bradykinin, and
histamine – target Gq/11-coupled GPCRs (Mehta & Malik, 2006). Given gravin’s role in
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supporting endothelial barrier integrity (Weissmuller et al., 2014), perhaps these agonists
stimulate endothelial permeability in part by redirecting PKA away from the cell
periphery through gravin redistribution.
Gravin’s putative interplay with these various GPCR pathways raises the
interesting possibility that gravin may be involved in a crosstalk mechanism between
Gq/11-coupled and Gs-coupled GPCR pathways. One very interesting line of
investigation might be found within GPCR families that couple to both G protein
pathways through various receptor classes, as is the case with purinergic P2Y receptors
and with adrenergic receptors. In these examples, both of the mentioned GPCR pathways
can be activated by a common agonist. ATP activates P2Y receptors, most of which are
coupled to Gq/11 (Erb et al., 2006). However ATP can also stimulate Gs-coupled
pathways through P2Y11 (Qi, Kennedy, Harden, & Nicholas, 2001) or adenosine receptor
activation if extracellular ATP becomes metabolized to adenosine through surfaceexpressed ectonucleotidases (Narravula, Lennon, Mueller, & Colgan, 2000). In the case
of adrenergic receptors, epinephrine/norepinephrine activates both Gq/11-coupled α1
adrenergic and Gs-coupled β-adrenergic receptors. Within both adrenergic and purinergic
systems, one could test how Gs-coupled GPCR signaling is impacted by the presence of
Gq/11-coupled GPCRs, and whether gravin affects this interplay. I predict that Gq/11
activation would trigger gravin/PKA redistribution and thereby impact Gs-mediated
subcellular PKA activity. This could very likely be the case in hippocampal neurons,
which express both gravin and multiple adrenergic receptor subtypes and have already
been linked in functions related to learning and memory (Havekes et al., 2012). Gravin
may be involved in regulating postsynaptic inputs through an interplay between dendritic
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GPCRs, or be more broadly involved in dendritic Ca2+ and PKA signaling as is the case
with AKAP79 (Dell'Acqua et al., 2006; Fuller, Fu, Scheuer, & Catterall, 2014; Gomez,
Alam, Smith, Horne, & Dell'Acqua, 2002; Murphy et al., 2014; Oliveria, Dell'Acqua, &
Sather, 2007; Oliveria, Dittmer, Youn, Dell'Acqua, & Sather, 2012). To test this idea, one
could begin with a thorough characterization of gravin expression in the hippocampus to
identify both the types of hippocampal neurons that express gravin and also the
subcellular localization of gravin within these neurons. Gravin redistribution could also
be assessed following stimulation of Gq/11-coupled GPCRs, such as α1-adrenergic
receptors. If α1ARs trigger gravin redistribution through Ca2+ and/or PKC mediated
pathways, it would be interesting to determine how this could impact β2AR signaling and
the interaction of β2AR with gravin. Knockdown or pharmacological inhibition of α1AR
and β2AR could also be performed to determine how these receptors might affect one
another upon norepinephrine stimulation in the presence of gravin.
Conclusions
In conclusion, the current study demonstrates that gravin mediates crosstalk
between calcium-dependent and cAMP-dependent signaling pathways. Under basal
conditions, gravin localizes PKA to the cell periphery which results in the potentiation of
plasma membrane PKA activity and the suppression of cytosolic PKA activity.
Intracellular calcium elevation causes gravin redistribution to the cytosol, which triggers
both the loss of PKA compartmentalization and loss of PKA potentiation at the plasma
membrane. Calcium therefore exerts control over cAMP-dependent signaling pathways
by altering the subcellular compartmentalization of PKA through gravin redistribution.
Although the physiological impact of this crosstalk mechanism is currently unclear,
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future research could lead to translational findings toward the treatment of disease. First,
a more detailed understanding of the mechanism behind gravin redistribution might lead
to pharmacological tools to regulate gravin distribution in vivo without the manipulation
of specific signaling networks. Second, many facets of vascular function could be
pursued in understanding gravin-mediated Ca2+/cAMP crosstalk including endothelial
cell migration, smooth muscle function, and cardiac contractility. Finally, knowledge of
gravin’s precise interplay between different GPCR-based signaling networks could be
usefully applied to other health and disease models, such as endothelial barrier function
and hippocampal learning and memory. The current study gives strong justification for
the exploration of gravin function within these contexts and paves the way for novel
therapeutic strategies and a more robust understanding of the complexity of cellular
signal transduction.
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ABBREVIATIONS
α1AR

α1-adrenergic receptor

AKAP

A-Kinase Anchoring Protein

AKAR3

A-Kinase Activity Reporter 3

ATP

adenosine triphosphate

β2AR

β2-adrenergic receptor

BAPTA-AM

1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid
tetrakis(acetoxymethyl ester)

BIM

bisindolylmaleimide

[Ca2+]i

intracellular calcium concentration

CAAX

C-terminal prenylated domain

CaM

calcium-calmodulin

cAMP

cyclic adenosine monophosphate

CB4

calmodulin binding domain 4

ECFP

enhanced cyan fluorescent protein

EGFP

enhanced green fluorescent protein

EYFP

enhanced yellow fluorescent protein

FRET

Förster’s Resonance Energy Transfer

Fsk

Forskolin

GPCR

G protein coupled receptor
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IBMX

3-isobutyl-1-methylxanthine

IM

ionomycin

InsP3

inositol triphosphate

kD

kilodaltons

Lck

N-terminal myristoylated and palmityolated domain

myr

myristoylation site

NES

nuclear export signal

PB1-3

polybasic domains 1 through 3

PDE4

phosphodiesterase type 4

PKA

protein kinase A

PKAc

catalytic subunit of PKA holoenzyme

PKC

protein kinase C

PLC

phospholipase C

RII

regulatory subunit of type II PKA

SERCA

sarco/endoplasmic reticulum calcium ATPase

SES

standard extracellular solution

SOCE

store-operated calcium entry

SSeCKS

Src-Suppressed C-Kinase Substrate

Tg

thapsigargin

WT

wild-type/full-length
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